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Abstract 
The neurotrophic protein Nerve Growth Factor (NGF) represents a 
new target for the development of potential therapies for neurological 
disorders such as Alzheimer's disease (AD). Peptides spanning the 
length of the hNGF sequence were assembled using both manual and 
automated solid-phase procedures. These sequences were tested in a 
competitive assay and their ability to inhibit 2 I-NGF binding to a 
recombinant form of the gp75 NGF-receptor assessed. Considerable 
levels of inhibitory activity were observed from peptides selected from 
the C-terminal fragment of the protein. The shortest sequence 
demonstrating this activity was found to span the amino acid residues 
Arg 100 to Arg 114. Removal of either residue from the sequence 
resulted in the inactivation of the peptide in the assay. This would 
appear to implicate both these basic side-chains in the receptor binding 
recognition process. 
Several peptides were investigated by high-field nuclear magnetic 
resonance spectroscopy (NMR) and a complete assignment of the 
spectra were made. Analysis of the through-space interactions indicated 






AcCoA acetylcoenzyme A 
Acm acetamidomethyl 
AD Alzheimer's disease 
Boc t-butyloxycarbonyl 
BDNF brain derived neurotrophic factor 
Bum butoxymethyl 
cDNA complementary DNA 
ChAT cholineacetyltransferase 
CNS central nervous system 
COSY correlated spectroscopy 






DMS 0 dimethylsuiphoxide 
DPPA diphenyiphosphorylazide 
DTT dithiothreitol 
EDT ethane- 1 ,2-dithiol 
EMS ethylmethylsuiphide 
FAB fast atom bombardment 
Fmoc 9-fluorenylmethoxycarbonyl 
GABA y-aminoisobutyric acid 
gp glycoprotein 
HOBt 1 -hydroxybenzotriazole 
HPLC high performance liquid chromatography 
HRMS high resolution MS 
5-HT 5-hydroxytryptarnine 
5-HTP 5-hydroxytryptophan 
HNGFR high affinity NGFR 
LNGFR low affinity NGFR 
M muscarinic receptor 
m multiplet 
Mab monoclonal antibody 
MS mass spectrometry 
mRNA messenger RNA 
A 
N nicotinic receptor 
NGF nerve growth factor 
NGFR nerve growth factor receptor 
NMR nuclear magnetic resonance 
NOE nuclear Overhauser effect 
NOESY NOE spectroscopy 
NTF neurotrophic factor 
NT 3 neurotrophin 3 
P polymer 
Pmc pentamethylchromansulphonyl 
PNS peripheral nervous system 
Pre precursor 
Resin copoly(styrene/ 2% divinylbenzene) 
RP reverse phase 
ROESY rotating frame NOESY 
S strong 
SDS sodium dodecyl sulphate 
SPPS solid phase peptide synthesis 
SAR structure activity relationship 
SRJF somatotropin release inhibitory factor 
S-t-butyl S-t-butyl sulphenyl protection 
TFA trifluoroacetic acid 
TFE trifluoroethanol 
TFMSA trifluoromethanesulphonic acid 
TLC thin-layer chromatography 
TNF tumour necrosis factor 
TOCSY totally correlated spectroscopy 
trityl triphenylmethyl 
trk tropomysin kinase 
UV ultraviolet 
Y leaving group 
Vii 
Amino Acids 
3-letter code 1-letter code 
a-Aminoisobutyric acid Aib - 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic acid Asp D 
Cysteine Cys C 
Glutamic acid Glu E 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Penicillamine Pen - 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 
Valine Val V 
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Chapter 1: Introduction 
1.1 Alzheimer's Disease. 
1.1.1 Introduction 
The signs and symptoms of neurological disorders, often bewildering 
in their clinical manifestations, present diagnostic and therapeutic 
challenges to both physicians and the pharmaceutical industry. Studies 
have shown that different neurological diseases are the result of the 
selective involvement of specific populations of cells. The specificity of 
a given cell type to a particular disease is termed 'selective vulnerability', 
and much of the recent research on the neurobiology of disease focusses 
on the causes and mechanisms that lead to the dysfunction and 
degeneration of neural cells in these human disorders. 
Interest in Alzheimer's disease (AD) has increased greatly in the last 
ten years. Demographic trends of increasing numbers of old people in 
developed countries have focussed attention on this condition which is 
associated with progressive and irreversible dementia, and is particularly 
prevalent in the elderly. Indeed at present AD affects a fifth of the over 
80's in the UK alone and is the fourth major cause of death after heart 
disease, cancer and stroke. 
The diagnosis of Alzheimer's disease can only be made with certainty 
after a close examination of the brain tissue. The disease is named after 
Alois Alzheimer who, in 1907, found two characteristic pathological 
changes, senile plaques and neurofibrillary tangles in the brain of a 
middle-aged woman dying demented with memory loss, disorientation 
and gross deterioration of intellectual function.' 
Biochemical findings have more recently shown that the chemicals 
inside the brain responsible for passing on information from neuron to 
neuron are present in lower levels than in healthy individuals. 234 These 
neurotransmitter deficits in the brains of patients with this disease have 
provided a focus for much of the current research efforts directed 
towards finding a cure for this illness. 
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1.2 Neurotransmitters in Alzheimer's Disease 
1.2.1 Introduction 
In most animals one can distinguish two major divisions in the nervous 
system. The central nervous system (CNS), which consists of the spinal 
cord and the brain and the peripheral nervous system (PNS) which 
serves to inform the CNS of stimuli, causing muscles and glands to carry 
out a response. The PNS can be divided into two groups. The sensory-
somatic system which controls our awareness of stimuli coming from the 
external environment and the autonomic system consisting of 
sympathetic and parasympathetic neurons which control mainly 
involuntary processes. The sympathetic neurons are stimulatory and 
control such events as increase in heart rate, bronchial dilation and 
conversion of glycogen to glucose. The parasympathetic neurons play an 
antagonistic role reversing the effects of sympathetic stimulation which 
could be harmful if prolonged unnecessarily. 
These critical events depend on the flow of information through 
elaborate circuits consisting of networks of neurons. Information is 
transferred from one cell to another at specialised points of contact: the 
synapse, and are most often made between the axon of one cell and the 
dendrite of another. At a synapse the axon usually enlarges to form a 
terminal button which contains spherical structures called synaptic 
vesicles, each of which holds a chemical neurotransmitter. On arrival of 
a nerve impulse some of the vesicles discharge their contents into the 
synaptic cleft. The neurotransmitter diffuses across the cleft to the post-
synaptic membrane of the next neuron and binds to a specific cell 
surface receptor. Conformational changes in this receptor results in the 
flow of ions such as sodium, potassium, chloride and calcium across the 
post-synaptic membrane and the firing of the next neuron results. Not all 
transmitters are excitatory, some bind to receptors and inhibit the flow of 
information. 
There are many different types of neurotransmitters used by nerve 
cells. The first neurotransmitters to be identified were acetylcholine 
secreted by the cholinergic system and the catecholamines dopamine, 
noradrenaline and adrenaline. Later investigators found that a number of 
unmodified amino acids sometimes serve as neurotransmitters. These 
2 
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include gamma-amino—butyric acid (GABA), glutamic acid (Glu), 
aspartic acid (Asp) and glycine (Gly). More recently studies have shown 
that some peptide hormones such as cholecystokinin (CCK), neurotensin 
(NT), substance P (SP), vasoactive intestinal peptide (VIP) and 
somatostatin (SRIF) act in a similar way often in cells which secrete 
other transmitters. These co-transmitters work together in a synergistic 
fashion to convey more subtle information than would be possible with a 
single transmitter. For a more detailed account of the nervous system 
and neurotransmitters the reader is referred to reference 5. 
1.2.2 The Cholinergic System 
Acetylcholine (ACh) was the first neurotransmitter to be discovered 
when in 1921 Loewi6 demonstrated that stimulation of the vagus nerve 
released a chemical that slowed the beating of an isolated frog heart. It is 
synthesised in the pre-synaptic nerve terminals from its precursor 
choline taken up from the blood supply (FIG 1.1). The reaction of 
choline with acetylcoenzyme A is catalysed by the cytoplasmic enzyme 
choline acetyltransferase (ChAT) and leads to the production of ACh. 
Propagation of the nerve impulse is achieved by release of ACh into the 
synaptic cleft followed by diffusion to the post-synaptic neuron where it 
binds to one of two families of receptor: nicotinic (N) and muscarinic 
(M). The former mediates the fast excitatory effects of ACh involving 
the opening of sodium channels, the latterIassociated with slower 
excitatory and inhibitory effects. ACh remaining in the synaptic cleft 
after stimulation is broken down again to choline by the enzyme 
acetylcholinesterase (AChE). Much of the choline freed by the 
hydrolysis is taken up once more by the pre-synaptic neuron. 
In the early 1970s biochemical analysis of the brains of AD patients 
were carried out and the results showed that there was a significant 
reduction in ChAT activity in the frontal cortex of these patients. 7 
Subsequent studies confirmed these results and further demonstrated 
reductions in ChAT as well as AChE activity, 8 .9 particularly in the 
hippocampus, an area known to be greatly affected by AD. A 
cholinergic deficit has therefore been proposed as an important factor in 
AD and as a result many current drug strategies are based in this area. 







drugs can interact in a manner which would increase the amounts of 
ACh present in the synaptic cleft. 
I 	1 
Signal transduction 	K 
FIG 1.1 Diagrammatic representation of the cholinergic synapse. Acetylcholine 
(Ach) is synthesised from choline by the action of the enzyme 
cholineacetyltransferase (ChAT) which transfers the acetyl group from 
acetylcoenzyme A (AcCoA). After diffusion to the post-synaptic membrane and 
signal propagation, excess Ach is broken down to acetic acid and choline by the 
enzyme acetyicholinesterase (AChE). 
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1.2.3 Augmenting Cholinergic Function 
There are several drugs available which enhance cholinergic function 
and so may be of potential benefit in AD' 0 (FIG 1.2). Administration of 
the precursor choline" (1) has been attempted in an analogous fashion to 
L-dopa in Parkinson's disease. Cholinesterase inhibitors such as 
tetrahydroaminoacridine 12 (Tacrine) (2) or physostigmine 13 (3) are 
capable of crossing the blood brain barrier and slowing down the 
breakdown of ACh. Agonists of nicotinic and muscarinic receptors such 
as arecoline 14 (4) and oxotremorine 15 (5) are available as well as drugs 
which directly stimulate ACh production such as 4-aminopyridine 16 (6). 
Clinical trials of many of these drugs have however shown 
improvements in many cases but none has as yet amounted to a cure. 
+ 
(CH3)3NCH2CH20H 








Oxotremorine (5) 	4-aminopyridine (6) 
FIG 1.2. Drugs effecting cholinergic function. 
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1.2.4 Noradrenaline (NA) and Serotonin (5-HT) 
There is evidence to suggest the presence of other deficits in AD 
although these do not seem to be as extensive as in the cholinergic 
system. As a result these deficits may not be related to disease severity. 
In the catecholaminergic system reduced levels of noradrenaline and 
also the reduced activity of the noradrenergic marker, dopamine - 
hydroxylase have been documented. 17 
Tyrosine hydroxylase 	 Dopamine-hydroxy1ase 
Tyrosine 	L-Dopa 	- Dopamine 	Noradrenaline 
There is also some evidence of an abnormality of the serotonin or 5-
hydroxytryptamine (5-HT) system in AD. 18 Serotonin is synthesised 
from L-tryptophan, present in the diet. This amino acid is actively 
transported across the blood brain barrier. 
Tiypiuphui hy diuAyi 
Tryptophan 	5-hydroxytiyptophan (5-HTP) 	5-HT 
1.2.5 Amino Acids and Peptides 
In contrast to the other major brain systems, changes in amino acid and 
peptide neurotransmitters appear to be less extensive. The release of 
GABA, aspartate and glutamate were not significantly affected in 
relation to controls. 19 Levels of the neuropeptide somatostatin however 
were reduced in some areas of the brain and moreover changes in this 
peptide may be associated with the severity of dementia. 20 
Although the cholinergic deficit remains the most widely accepted 
biochemical hypothesis 21 for cognitive decline in AD it now seems 
unlikely to account for the entire range of biochemical deficits in 
Introduction 
dementia. This is particularly noticeable in the rather questionable 
results obtained in clinical trials of many of the varied drugs available 
which interfere with cholinergic function. 22 As a result, scientific 
investigations have begun to look at other strategies in a bid to combat 
neurological disorders. These investigations have begun to uncover a 
variety of neurotrophic factors 23 (NTFs) which may perhaps be utilised 
in therapeutic approaches to influence, restore and replace components 
of neural circuits injured by disease. 4,25 
NTFs are proteins that promote the maintenance, growth and 
functional performances of populations of neurons. 26 It appears likely 
that different types of neuronal cells are supported by specific proteins 
which exert their influence on neuronal cells from early embryonic 
stages. During early development, massive neuronal cell death occurs 
around the time when axons meet their innervation territory. Escape 
from this developmental cell death seems to depend on the acquisition of 
neurotrophins from the surrounding tissue. Only those neurons supplied 
with NTFs promote life sustaining activities. 2728 These crucial agents 
are important throughout the entire life of the cell and deficits may be 
responsible for certain types of neurological conditions. 
7 
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1.3 Neurotrophic Factors 
1.3.1 Introduction 
The fundamental importance of NTFs in stimulating growth and 
maintaining viability in a given cell type has become a generally 
accepted principal of developmental biology. The role of these proteins 
as chemical messengers which coordinate cellular activities means they 
can be classified as hormones. Of the three known mechanisms for 
hormone transport to responsive tissue (FIG 1.3) NTFs appear to be of 
the paracrine type, that is, their mode of transport to target tissue is by 
diffusion rather than through the blood stream. 29 In the nervous system 
therefore it is the cells surrounding a given neural network which are 
thought to secrete NTFs in a steady stream. These may be glial cells, 
oligodendrocytes, astrocytes or the Schwann cells which surround and 
protect the axon. The secreted NTF then diffuses to the membrane of 
responsive neurons and binds to a specific cell surface receptor. Once 
again a conformational change is induced in the receptor and signal 
transduction results. When this message reaches the nucleus, 
transcription soon follows and a host of enzymes and structural proteins 
are produced which are essential for the maintenance of healthy 
function. 30 The diversity of production of so many biochemically 
important molecules by neurons on exposure to NTFs makes this a more 
general target for drug design. Agonists directed specifically against 
receptors of NTFs therefore provide an attractive alternative to the rather 
limited functions of the current drug strategies. 
000 0 







Endocrine Paracrine 	 Autocrine 
FIG 13. The different systems used for the transport of hormones. 
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1.3.2 The Nerve Growth Factor 
The neurotrophic factor Nerve Growth Factor (NGF) is the subject of 
our investigations. It is the best characterised growth factor and so 
serves as a paradigm for more recently discovered molecules. 
The discovery of NGF in the early 1950s was a landmark in 
developmental neurobiology. In 1948 Beuker 31 reported the results of an 
imaginative experiment consisting of the grafting of fragments of a 
mouse tumour to the body wall of a three day old chick embryo. 
Observation of the embryos after 3-5 days showed that sensory nerve 
fibres from the embryo had grown into the tumour. In 1951 Levi-
Montalcini and Hamburger32 '33 showed that this innervation was caused 
by a specific diffusible substance secreted by the tumour. The attempted 
purification of the factor from the tumour led to the fortuitous discovery 
of NGF in snake venom in concentrations 1000-fold higher than in the 
tumour. 34 Subsequent examination of the tissues homologous to the 
snake venom gland uncovered the fact that the submaxillary gland of the 
adult male mouse is rich in NGF. The latter tissue has since become the 
preferred source for the purification of the growth factor 35 and has 
provided NGF in sufficient quantities to allow an extensive 
characterisation of the protein at the structural level. 
In 1971 Angeletti and Bradshaw 36 published the complete amino acid 
sequence of the polypeptide chain and this is shown in FIG 1.4. The 
protein consists of two non-covalently linked 118 residue chains with an 
NH2-terminal serine and a CO 2H-terminal arginine. The three intrachain 
disulphide bonds bridge most of the chain, leaving relatively short free 
segments at either end of the chain: 14 residues at the N-terminus and 
only 8 residues at the C-terminus. A single methionine occupies position 
9, three tryptophan residues are located in positions 21, 76 and 99 and 
two tyrosines at positions 52 and 79. 
Analysis of a mouse cDNA clone has shown that the mature NGF 
protein is generated by proteolytic cleavage from a 305 residue 
precursor, termed pre-pro NGF.37 The NGF gene has also been isolated 
from several other species, and the nucleotide sequence analysis has 





FIG 1.4. The primary amino acid sequence of mouse NGF. 
1.3.3 Nerve Growth Factor and Alzheimer's Disease 
In 1983 Hefti43 published the hypothesis that a lack of NGF in the 
cholinergic neurons of the basal forebrain could be a crucial factor in the 
pathogenesis of AD. To back this hypothesis he produced in the 
laboratory animals with experimentally induced lesions. 44  Transection of 
the cholinergic pathway running from the septum to the hippocampus 
provided a model system for the study as this area of the ascending 
cholinergic system is known to degenerate in AD.45 NGF was 
administered directly into the ventricles of these animals through 
cannulas and its effects on cholinergic function and behaviour was 
monitored.46 Analysis revealed that NGF infusion was enough to rescue 
the neuronal population in this area from almost certain cell death. 47 In 
10 
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untreated lesioned animals the number of surviving neurons fell 
dramaticallyA 
In behavioural tasks48 untreated animals showed a reduced ability to 
perform. These animals exhibited a reduced ability to learn a radial maze 
task whereas treated animals counteracted this lesion-induced deficit and 
learned the maze problem much more rapidly. These findings suggest 
that improvements reflect the survival of cholinergic neurons in this area 
of the brain and that cholinergic systems have a major involvement in 
memory function. 
Given the important role NGF plays in cellular function it could well 
be that a lack of endogenous NGF or a reduced response to NGF is 
indeed a major contributory factor in cellular degeneration. Increasing its 
availability may stimulate synthetic processes within cells which would 
strengthen and maintain cell viability and increase electrical excitability 
and neurotransmitter synthesis. Neurons would then be less vulnerable to 
the primary disease process and as a consequence have a higher 
probability of survival. 
1.3.4 Nerve Growth Factor Biology 
NGF has been extensively characterised in its role as a specific 
neurotrophic factor for peripheral sympathetic neurons. 4950 It is 
synthesised in the periphery by the target tissues of the sympathetic 
neurons and acts on specific receptors located on the neuron. These 
receptors mediate local actions of NGF by transmitting signals to the cell 
body where proteins essential for the survival and expression of 
transmitter specific properties are synthesised. In some sympathetic 
neurons this results in the stimulation of the key enzymes for the 
production of noradrenaline, the neurotransmitter used by these 
neurons. 51 
NGF also seems to influence the peripheral sensory system and in 
particular plays a role in the maintenance of peptidergic neurons 52 where 
the transmitters include substance P, somatostatin and cholecystokinin. 
In recent years accumulating evidence has shown that NGF acts as a 
neurotrophic agent for cholinergic neurons of the CNS in a way similar 
to the peripheral sympathetic neurons. 53 In studies of rat brain, NGF 
11 
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levels were found to be highest in areas corresponding to the ascending 
cholinergic neurons of the basal forebrain. 54 
In addition to its ability to increase the synthesis of enzymes involved 
in transmitter biosynthesis NGF has a variety of other effects on its 
target neurons. Some of these are listed below in Table 1. 
Biological Effect Reference Nos. 
Increased neurite activity 55 
Chemotactic role 56,57 
Increase in tyrosine hydroxylase, dopamine 	- 
hydroxylase and N-phenylethanolamine-N- 
methyltransferase  
51,58 
Cholineacetyliransferase activity increased 
by NGF  
23,59 
Increase in ornithine decarboxylase activity 60 
Stimulation of amino acid uptake 61 
Increased activity of acetyicholinesterase 62 
Increase in acetylcholine sensitivity and 
electrical excitability  
63 
Increase in peptidergic neurotransmitter 
synthesis  
52 
Changes in proto-oncogene transcription 64 
Protein phosphorylation 65, 66, 67 
Table 1 : The biological effects of NGFon target neurons. 
It is the multiplicity of effects stimulated by NGF on receptor 




1.4 The Nerve Growth Factor Receptor (NGFR) 
1.4.1 Introduction 
The many physiological effects of NGF on selective neuronal 
populations are the result of its initial interaction with a specific cell 
surface receptor. A knowledge of the structure, function and regulation 
of the NGFR is essential to understanding the mechanism of signal 
transduction. Among the many NGF responsive cell types, the clonal 
cell line Pci 268  has become the model of choice for understanding the 
mode of action of NGF. These cells from a transplantable 
pheochromocytoma rat tumour respond to treatment with NGF and 
produce some of the biological effects described above. 69 
Studies in these cells using mouse NGF revealed two distinct affinity 
states for the NGFR. It was found that 10-15% of the receptors displayed 
high affinity binding 70 with a Kd  of 10-11  M with the remainder 71 
possessing a Kd  of 10-9 M. The difference in equilibrium binding is 
accounted for by a 100-fold difference in the rate of dissociation of 
NGF, thereby designating high and low affinity receptors as 'slow' and 
'fast' receptors respectively. 
In 1986 Green72 demonstrated the importance of the high affinity 
binding form of the NGFR by producing a series of PC12 cell lines 
which exhibited only low affinity binding characteristics. These cells 
showed no biochemical or morphological responses to NGF treatment. 
1.4.2 The Low Affinity NGFR (LNGFR) 
The identity of the NGFR was clarified by the development of murine 
monoclonal antibodies (Mab) directed against what turned out to be the 
LNGFR. 73 The LNGFR is an acidic glycoprotein74 with an apparent 
molecular weight of about 75000-daltons (gp75NGFR).  Using the anti-
LNGFR Mabs, the human 75 and rat76 receptors were cloned by the 
method of gene transfer and cDNA clones for the human, rat and 
chicken77 revealed that it is a highly conserved protein which can be 
divided into several distinct domains. The human LNGFR has a 
hydrophobic signal sequence, a single N-linked glycosylation site, four 
cysteine rich repeat units in the extracellular domain, a single 
13 
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transmembrane domain, and a 155 amino acid cytoplasmic domain. The 
cytoplasmic domain75 is unusual in the fact that it neither reveals the 
presence of an ATP binding site, nor bears any other resemblance to 
other growth factors with intrinsic protein kinase activity (FIG 1.5). 
Sequence comparison has shown that the cysteine rich region has a 
significant degree of homology with the T-cell activation molecule 78 
0X40, the B-cell activation molecule 79 CD40 and the tumour necrosis 
factor80 (TNF). This suggests that there may be a family of related 
receptor molecules. 
After the cloning of the LNGFR, many investigators were eager to 
elucidate the role of the LNGFR in signal transduction. The lack of an 
NGF-induced response in cells expressing only the LNGFR clearly 
indicated that LNGFR is not a responsive receptor on its own. It did 
however, from chemical cross-linking studies, appear to be associated 
with high affinity binding and further examination suggested that it does 
have a critical role to play in signal transduction. 81 





C 	 d 







FIG 1.5. The amino acid sequence of the LNGFR. Region a-b = signal 
sequence, b-c = extracellular domain, c-d = transmembrane domain 
and d-e = cytoplasmic domain. 
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1.4.3 The High Affinity NGFR (HNGFR) 
During the course of this research and once again using chemical 
cross-linking techniques a second cell surface protein was found which 
along with the gp75NGFR protein exhibited high affinity binding. 8 ' 
Because of the lack of an obvious LNGFR signal transduction domain 
and reports that NGF induces protein phosphorylation on tyrosine many 
investigators suspected that the HNGFR was a tyrosine kinase. Meakin 
and Shooter82 detected this protein using disuccinimidyl suberate as 
cross-linking reagent and found that anti-phosphotyrosine antibodies, but 
not anti-LNGFR antibodies reacted with cross linked product. 
This receptor protein was found to be a member of a tyrosine kinase 83 
gene family. It was identified from a colon carcinoma biopsy 84 and was 
found to be part of the product of a human transforming gene: the trk 
oncogene. This oncogene was generated from a genomic rearrangement 
that fused a tropomyosin gene with a novel tyrosine kinase, the trk 
proto-oncogene. It has since been shown that the trk proto-oncogene 
product codes for a tyrosine kinase cell surface receptor and that this 
protein forms part of the HNGFR. 85 
The trk proto-oncogene codes for a protein of 790 residues. 86 It 
consists of a 32 residue signal sequence, an amino terminal moiety from 
residues 33 to 407 rich in sites for N-glycosylation, a transmembrane 
domain and a catalytic cytoplasmic region highly related to that of other 
tyrosine kinases. The product is a 140000-dalton glycoprotein which has 
been designated gpl40 proW-Irk  (FIG 1.6). The identification of trk as a 
part of the HNGFR led to a search for related molecules that might be 
receptors for other neurotrophic factors. The irk B gene was cloned on 
the basis of its homology to trk 87 and like ti-k, ti -k B encodes a tyrosine 
kinase intracellular domain. The tyrosine kinase domains associated with 
these proteins are virtually identical but the sequences of the 
extracellular ligand binding domains are only about 30% identical. Two 
recent studies assigned trk B as the receptor for brain 
neurotrophic factor 88 (BDNF) and neurotrophin 3 (NT3) 89 which are 
closely related in sequence to NGF and are members of the same 
neurotrophin family. It appears likely therefore that the high degree of 
specificity is achieved through binding to critical elements on the 
extracellular domain of the various proto-oncogene products. 
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a 	 b 
MLRGGRRGQLGWHSWAAGPGSLLAWLILASAG/AAPCPDACCPHGSSGLRCTRDGAL 24 





RLNQPTHVNNGNYTLLAANPFGQASASIMAAFMDNPFEFNPEDP IPDTNSTSGDPVE 37 





LAGLHFVHRDLATRNCLVGQGLVVKIGDFGMSRDIYSTDYYRVGGRTMLP IRWMPPE 661 
SILYRKFTTESDVWSFGVVLWEIFTYGKQPWYQLSNTEAIDCITQGRELERPRACPPE 719 
e 
VYAIMRGCWQREPQQP..HS IKDVHARLQALAQAPPVYLDVLG 	 758 
FIG 1.6. The amino acid sequence of the human trk receptor. Region a-b = 
signal peptide, b-c = extracellular domain, c-d = transmembrane domain, d-e = 
catalytic cytoplasmic domain. 
16 
Introduction 
The current hypothesis relating to the NGF-receptor interaction is that 
high affinity binding, and hence signal transduction, is achieved only on 
association of NGF with the two receptor subunits detailed above. 85 The 
components, the trk gene product gpl4O proto-trk  and gp75 NGFR  each bind 
NGF with low affinity, but in conjunction these proteins are capable of 
transmitting the signal across the membrane of responsive neurons. It is 
possible to envisage a receptor binding site composed of structural 





FIG 1.7. Hypothetical binding of NGF to both receptor units. 
The role of the gp75 NGFR  in signal transduction has been studied. In 
cells which have been engineered to produce a mutant form of the 
LNGFR lacking portions of the highly conserved cytoplasmic domain no 
high affinity binding was observed. In addition these mutant cells lack 
normal tyrosine phosphorylation of cellular proteins in response to NGF 
suggesting that interaction of the cytoplasmic domains of both receptors 
are essential for signal transduction. 90 It has also been demonstrated that 
the other members of this family of neurotrophins BDNF and NT3 bind 
to the LNGFR with similar affinity to NGF. 91 This seems to suggest that 
the LNGFR belongs to a general receptor class for this family of proteins 
and that the different forms of the irk proto-oncogene products, irk B 
and irk C confer the high degree of specificity shown by these. proteins 
for different cell types. 
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1.5 Signal Transduction 
1.5.1 Introduction 
Only after the discovery of the trk receptor has the evidence started to 
accumulate on the mechanism of action of NGF with any degree of 
certainty. Even at this early stage it appears that NGF binding to its 
receptor results in the stimulation of multiple second messenger 
pathways of high complexity. Stimulation of these pathways results in 
the modification of cellular proteins which elicit specific gene 
expression changes. These activated genes known as 'primary response 
genes ' lead to the production of proteins called transcription factors 
which act as switches at the genomic level and trigger a subsequent 
wave of gene inductions and repressions. 92 
It has also been suggested that intemalisation of the NGF-receptor 
complex is important in signal transduction. In 1974, Hendry et al. 93 
provided evidence that NGF is taken up at nerve terminals and 
retrogradely transported to the cell body. This implies that NGF has an 
intracellular site of action and one possible site for this interaction is the 
nucleus. In one study evidence was presented of a receptor for NGF in 
the nucleus94 and, more specifically, associated with the chromatin. In 
another, evidence was presented for the association of the NGF-receptor 
complex with the nucleus after internalisation. 95 However both studies 
were placed in some doubt when Bothwell 96 showed that contamination 
of the nuclear preparations with NGFR was a likely explanation. It 
would therefore appear that intemalisation of the NGF-receptor complex 
results in either degradation in the lysosomes or dissociation of the 
complex followed by recycling back to the cell surface. 
1.5.2 Second Messengers in Signal Transduction 
The best model so far proposed for signal transduction is based on the 
mechanism already established for epidermal growth factor 97 (EGF). 
When NGF binds to the HNGFR a conformational change results in the 
intracellular portion of the receptor. This conformational change 
activates the trk receptor and stimulates autophosphorylation of tyrosine 








primed in this way acts as an enzyme for substrates which are similarly 
phosphorylated on tyrosine. Signal transduction is thereby activated and 
a phosphorylation cascade is initiated (FIG 1.8). 
PLC 
Phosphorylation events 
Protein synthesis 4 	mRNA 
Cell 
nucleus 
FIG 1.8. Signal transduction in the NGF-receptor system. 
One of the substrates appears to be the protein phospholipase C 
(PLC).98 This membrane bound enzyme is critical in the 
phosphoinositide cascade where it hydrolyses a phosphodiester bond of 
phosphatidyl inositol 4,5- bisphosphate resulting in the generation of two 
messengers - inositol 1 ,4,5-triphosphate (1P 3) and diacylglycerol. 
Among the other known substrates for the activated NGF-receptor are 
GTPase activator protein 99 (GAP), and several other kinases including 
microtubule associated protein' 00 (MAP), raO', and phosphatidyl 
inositol kinase. 102 
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Most of these substrates are not specific for NGF alone. The same 
cascades are found when other receptor systems are activated in 
response to extracellular stimuli. Because the neurotrophic effects of 
NGF are unique it seems likely that other substrates exist which are 
specific to NGF alone. Discovery of these substrates and deciphering the 
transduction pathways by which they operate offers tremendous 
potential for understanding the molecular nature of neural development. 
This may lead to the design of new pharmacological approaches to 
human neuropathies. 
For a more detailed account of these and other substrates as well as a 
more complete picture of the signalling process the reader is referred to a 
recent review by Cantley et al. 103 
1.6 The Potential Pharmacological use of NGF 
There are four possible strategies which can be envisaged to enhance 
the biological processes which occur when NGF binds to responsive 
neurons: 
Intracerebral Administration of NGF. 
As proteins do not cross the blood brain barrier the intracerebral 
administration of NGF would be the only way of reaching neuronal 
populations in the brain. In experimental animals this has already been 
successfully achieved by the use of osmotic minipumps, 46 however there 
are several drawbacks to such a delivery system. It is an invasive 
procedure requiring skilled surgery and questions have also been raised 
about the stability of proteins in the minipump itself during storage. 
Perhaps an alternative procedure could utilise I new developments in 
slow release polymer systems which are currently being used for 
delivery of peptide drugs in peripheral disorders such as prostate cancer 
treatment. 104,105 
Neuronal Grafting. 
Intracerebral grafting as a method of reversing degeneration has been 
the focus of much research recently. 106 One method of delivering trophic 
factors to the brain is through genetically modified cells which secrete a 
neurotrophic substance. Rosenberg 107 demonstrated that the genetic 
modification of cells could be used to produce NGF and to enhance the 
survival of axotonised cholinergic neurons within the brain. Cells 
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similarly modified to produce other trophic factors may also be effective 
as vehicles for delivering trophic substances to other neural tissues such 
as in the catecholaminergic system. To date, genetically modified cells 
grafted into animal models of Parkinson's disease have been engineered 
to produce catecholamines rather than trophic factors. 108 
The use of grafts as a technique for repairing degenerating neurons is 
certainly an intriguing possibility. Whether the time has arrived for more 
therapeutic application of this procedure appears at the moment to be a 
point of contention. 
3. Augmentation of Endogenous NGF Levels. 
To produce a therapeutic agent capable of boosting NGF 
concentrations requires a detailed knowledge of how growth factor 
synthesis is regulated within cells. One potential target area is gene 
activation and this is controlled in part by proteins called transcription 
factors. 109 These proteins appear to exert their effects on transcription 
after binding to a specific sequence of DNA bases usually sited in the 
promoter region of the gene. Recently Landschulz et al. 110 became the 
first to recognise that some of these proteins share a heptad repeat of 
leucine residues, i.e. a sequence in which single leucine residues are 
repeated at several intervals of seven residues. The polypeptide 
segments containing these periodic arrays of leucine residues are 
proposed to exist in an a-helical conformation, with the leucine side 
chains extending from one a-helix interdigitating with those displayed 
from a similar segment of a second polypeptide facilitating dimerisation. 
This hypothetical structure is referred to as the 'leucine zipper.' 
Leucine zipper proteins can be divided into several families on the 
basis of the properties of polypeptide regions adjacent to the zipper. One 
such family contains a high positive charge immediately adjacent to the 
amino terminus of the zipper domain. This family, referred to as the 
bZIP family' 11 can be further divided into several subfamilies according 
to the degree of similarity of the amino acids in the zipper and basic 
regions. 
Two of these subfamilies appear to be involved in NGF gene 
activation. 112 A heterodimer of the proto-oncogenes c-fos and c-jun 
called transcription factor AP-1 has been shown to bind a consensus 
recognition site present in the first intron of the NGF gene and appears 
to be important in regulating its transcription. 113  It has been confirmed 
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by DNAase footprint experiments' 14 that the AP-1 consensus sequence 
TGAGTCA binds the heterodimer. Other experiments have shown that 
lesion of the sciatic nerve causes a rapid increase in the levels of c-fos 
and c-jun mRNA which was closely followed about 2 hours later by an 
increase in NGF mRNA. 112 
An increasing knowledge of how these proteins bind to particular 
sequences of DNA and induce transcription may lead to the design of 
gene specific therapies tailor-made to enhance or inhibit gene 
expression. 
4. NGF Receptor Agonists. 
The development of an NGF receptor agonist seems at present to offer 
the most attractive possibility for influencing responsive neural 
populations. The blood brain barrier however represents a considerable 
obstacle which has to be overcome in targeting central nervous system 
disorders. The restrictions on the size and nature of potential drug 
candidates makes the task an even more complex one. Suitable 
compounds may be found using two possible strategies. Firstly, modem 
mass screening techniques allow for the rapid testing of huge compound 
libraries and many interesting leads have been discovered in this way. 
Secondly, a more rational approach to drug design can be adopted 
whereby protein fragments are synthesised and assayed to determine the 
minimum functional unit. Careful analysis of such a sequence may also 
lead to the development of potential therapies. So far very little is known 
about the possibility of producing active NGF fragments. A trypsin 
15 of NGF, claimed to be effective several years ago was later 
shown to be inactive.' 16  The lack of demonstrated success however does 
not prove that such an approach is not viable. Fragments of fibronectin 
were shown to possess biological activity 117 as were analogues of 
insulin-like growth factor 1 (IGF-1). 118 
1.7 Project Aims 
A key to the understanding of growth factor induced changes in 
cellular systems lies in the way the protein hormone binds to its receptor. 
The major molecular interactions involved in ligand receptor binding are 
Van der Waals interactions, electrostatics, hydrogen bonding and 
hydrophobic effects. A subtle blend of these interactions coupled with a 
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well defined conformational requirement are essential in providing the 
high degree of specificity in these systems. In the case of NGF very little 
is known about the amino acid sequence elements required for binding 
to gp75NGFR and to the trk receptor. It is the primary aim of this project to 
try and shed some light on this rather grey area. 
In recent years breakthroughs in recombinant DNA technologies have 
provided a much needed impetus for studies of structure-function 
relationships (SARs). This study was made possible by the engineering 
of recombinant gp75NGFR and the subsequent development of a 
competitive binding assay by our collaborators, Parke-Davis and Chiron. 
Advances in the area of solid phase peptide synthesis (SPPS) over 
recent years have also contributed greatly to our understanding of 
molecular recognition and signal transduction. The routine synthesis of 
peptide sequences spanning regions of many different peptide hormone 
systems has led to the discovery of smaller, highly potent molecules 
with antagonistic or agonistic qualities. 119 This study of the larger 
polypeptide hormone NGF is an attempt to dissect the protein sequence 
and determine the minimum sequence required for receptor binding. The 
obvious significance of the biological effects produced when NGF binds 
to its receptor makes it an attractive target for drug design. It is hoped 
this work will provide an insight into the structural requirements needed 
for ligands binding at the NGF receptor. 
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1.8 Solid Phase Peptide Synthesis (SPPS) 
1.8.1 Introduction 
In the early 1960s the concept of solid phase peptide synthesis was 
conceived by R.B. Merrifield. 120 The rationale for the approach was 
simple. By attaching a growing peptide chain to an insoluble polymeric 
support, it was reasoned that the excess reagents and byproducts from 
the coupling reactions could be removed by simple filtration and 
washing steps. This circumvented the need for a laborious purification 
step implicit in the methodology of classical solution phase peptide 
synthesis. This new method of peptide assembly was also entirely 
compatible with some of the well developed chemistry of coupling and 
functional group protection which already existed at this time. 121 Since 
the early developments in this area SPPS has become a major discipline 
as is evinced by the numerous publications on this subject. 
1.8.2. The Solid Phase Principle 
There are four principle features which have led to the great success of 
the solid phase technique. 
The peptide is assembled while it is attached to a polymer support. 
This allows for the ready separation of product from unreacted material. 
By using suitable excesses of reagent it is possible to drive each 
coupling step to completion. 
Mechanical losses are minimised by retaining the peptide-polymer 
beads in a single reaction vessel throughout the synthesis. 
Physical manipulations are easy, rapid and amenable to automation. 
The peptide can therefore be assembled by the stepwise addition of 
activated amino acids to a resin bound linker. Naamino acid protection 
is essential to prevent polymerisation and racemisation in the activated 
state. The easy removal of Naprotection before the addition of the next 
amino acid is also a prime requirement. The reaction conditions 
employed in this deprotection should not affect the protecting groups on 
the side chains of sensitive amino acids. Peptide assembly can therefore 
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FIG 1.9. The synthesis cycle for Fmoc SPPS. 
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1.8.3 The Solid Support 
In his search for the ideal solid support, Merrifield investigated several 
different polymer types. The one which showed most promise was a 
chloromethylated copolymer of styrene and 2% divinylbenzene. 120  This 
resin in the form of 200-400 mesh beads, possessed a porous gel 
structure which allowed ready penetration of reagents especially in the 
solvents required for peptide synthesis. Despite much research and the 
development of new supports including the successful application of 
polyacrylamide resins 122 the original chloromethylated polystyrene resin 
remains the preferred starting point for most syntheses. 
The chloromethylation of the resin produces an arylchloromethyl 
derivative (7) which can be used as an anchor for the growing chain. To 
this can be coupled a variety of ' handles ' which allow for the easy 
cleavage of the peptide from the resin on completion of the peptide 
assembly. The handle of choice used in this laboratory for the 
preparation of C-terminal peptide acids was developed by Wang 123 (8). 
This linker is easily cleaved in trifluoroacetic acid solutions. The 
synthesis and mechanism of cleavage of this handle are shown in FIG 
1.10 a. and b. 
HO''rN + 
OH 













FIG 1.10. The synthesis (a) and cleavage (b) of the Wang linker. 
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The preparation of C-terminal amides is achieved using the 
dibenzosuberenyl derivative (FIG 1.11) which has recently been 
developed in this laboratory.'' This linker is once again cleaved by 
TFA solutions. 
NH—PEPTIDE 
OCH - RESIN 
FIG 1.11. Linker used for the generation of peptide amides. 
1.8.4 Protecting Groups in Solid Phase Peptide Synthesis 
In peptide synthesis it is necessary to block those groups on the amino 
acids which are capable of reaction but which are to be free in the 
product by using protecting groups (FIG 1.9). These groups must be 
selected so that they can be removed without disturbing the peptide 
bonds formed. In the case of the Naamino group this is most commonly 
achieved using urethane derivatives. 
The most widely used urethane protecting group is the 9-
Fluorenylmethoxycarbonyl (Fmoc) group, which was introduced by 
Carpino 125 and applied to solid phase peptide synthesis by 
Meienhofer. 126 The Fmoc group is removed within seconds by 
secondary amines such as piperidine (20% in dimethylformamide). 
Tertiary amines are relatively ineffective in cleaving Fmoc groups, and 
the low and rapidly declining concentration of resin bound primary 
amine does not cause detectable cleavage during coupling reactions. The 
mechanism of cleavage is by a n-elimination. The olefin (9) generated in 
the reaction is trapped as its piperidine adduct as shown in FIG 1.12. 
This adduct (10) absorbs strongly in the UV. Quantitative measurement 

















(1 	 + NH2R 
FIG 1.12. The cleavage of the Fmoc protecting group by piperidine. 
There are many sensitive side chains contained in the common amino 
acids found in proteins. These include the thiol groups of cystèine, the 
hydroxyamino acids serine, threonine and tyrosine and the carboxy 
groups of aspartic and glutamic acid. Basic side chains include the 
amino and guanidino groups of lysine and arginine as well as the 
imidazole function of histidine. As a consequence a range of semi 
permanent protecting groups have been developed, most of which are 
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easily removed in acids such as trifluoroacetic acid (TFA) on completion 
of the synthesis with concomitant generation of the free peptide. The 
protecting groups of choice used in this laboratory are summarised in 
Table 2. 
Amino Acid Side-chain Protecting Deprotection 
Group Conditions 
Ala, Phe, lie, Leu, Met, No protection required 
Asn, Pro, Gin, Val, Gly, - 
Trp  
Cys S-acetamidomethyl Hg2 ions, 121  silver triflate 
S-triphenyimethyl TFA 
S-t-butylsulphenyl tributyiphosphine, thiols 
Asp, Glu, Thr, Ser, Tyr t-butylester TFA 
Lys t-butyloxycarbonyl TFA 
His N(ir)-t-butoxymethyl 127 TFA 
Arg pentamethylchromansuip- TFA 
hony1 128  
Table 2. Protecting groups in SPPS 
1.8.5 Cysteine Protection and Disulphide Formation 
A wide range of S-protecting groups for cysteine have been recorded 
in the literature. 129 Those considered suitable for the synthesis of the 
peptides detailed in this thesis are shown in FIG 1.13 and include the S-
acetamidomethyl, 130 S-triphenylmethyl, 131 and the S-t-butylsulphenyl 
groups. 132 The different cleavage conditions for each of these protecting 
groups also offers the possibility of selective disulphide bond formation. 
This is a major advantage in the synthesis of peptides containing 
multiple S-S bridges. 
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S•cetamidomethyl (Acm) (11) is generally stable to both mild acids 
and base, 130 but is rapidly cleaved by a range of electrophilic reagents, 
notably mercury(][[) ions,130 silver triflate, 133 and iodme. 134 The latter 
reagent yields disulphides directly as does the reagent thallium(ffl) 
trifluoroacetate. 135 Of the three protecting groups considered the Acm 
group has particular appeal for hydrophobic sequences. This group 
reduces the overall lipophilicity of the growing peptide chain and also 










FIG 1.13. Protecting groups used for cysteine. 
Reactivity of a very different sort is shown by the S-t-butylsulphenyl 
derivative (12). The same stability to mild acids and bases is present, but 
the cleavage is by reduction of the disulphide bond typically by 
phosphines 136 or thiols. 137 This protecting group is therefore 
complementary to Acm. 
The S-triphenylmethyl (trityl) (13) group is readily removed in acids 
and so thiol peptides are produced directly from cleavage under standard 
conditions. The trityl group can also be removed by treatment with 
iodine. The observation by Kamber et al. 138 that the reactivity of the 
trityl and Acm groups differ considerably depending on the solvent, 
means that selective disulphide formation can be achieved using these 
two groups. 
Other methods of intramolecular disulphide formation in peptides 
containing only two cysteine residues include air oxidation, 139 10% 
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dimethylsuiphoxide (DMSO) in TFA' 40 and oxidants such as potassium 
ferricyanide.' 41 
1.8.6 Peptide Bond Formation 
The formation of the peptide bond in SPPS generally requires mild 
reaction conditions and the activation of the amino acid carboxy group. 
Amino acid activation can readily be achieved by the incorporation of a 
suitable electron withdrawing leaving group (Y) which has the effect of 
increasing the electrophilicity of the carboxyl carbon atom and thus 
facilitates the nucleophilic attack of the amino group (FIG 1.14). 
Cb 
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1.14. Peptide bond formation. 
The tetrahedral intermediate formed (14) leads to the stabilised amide 
bond by the elimination of Y. There are numerous possibilities for the 
leaving group Y and many different types of activation procedures have 
been used successfully in peptide synthesis. One of the most commonly 
used is the symmetrical anhydride (18). There is no ambiguity 
concerning which carbonyl is attacked by the amino component, a 
concern when using mixed anhydrides, and they react exceptionally 
cleanly and in high yield. Symmetrical anhydrides are also stable and 
have been stored for long periods of time but are most commonly 
prepared immediately before use with a reagent such as 
diisopropylcarbodiimide (DIC) (15). DIC reacts with amino acids to 
form an 0-acylurea (16). However in the presence of a further 
equivalent of amino acid the adduct quickly reacts forming the 
symmetrical anhydride with the displacement of diisopropylurea. In a 
similar manner the adduct can react with an equivalent of 1- 
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hydroxybenzotriazole (HOBt) (17) generating the activated HOBt ester 
(FIG 1.15). Both these methodologies have been successfully employed 
in the synthesis of most of the peptides detailed in this dissertation. 
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FIG 1.15. Coupling procedures used in SPPS 
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Chapter 2: Discussion 
2.1 Selecting Peptides for NGF-Receptor Studies 
2.1.1 Introduction 
One of the fundamental challenges in designing small peptide ligands 
for biological receptors from larger protein hormones is the identification 
of the critical amino acids involved in the binding interaction. 
Knowledge of which amino acid residues are important for binding of 
NGF to its receptor, and those which are essential for the biological 
activity of the factor, may provide insights into the molecular 
mechanisms whereby NGF exerts its neurotrophic effects. This 
information, it is hoped, may eventually lead to an NGF agonist or 
antagonist of potential clinical benefit. There are several methods which 
can be employed to derive this type of information. 
Firstly, since the publication almost a decade ago of the construction 
of specific protein variants using recombinant DNA technology, 142 the 
science of protein engineering has become almost routine. After a period 
of initial scepticism it now appears that proteins are highly resilient 
structures ideally suited for engineering. They can tolerate sequence 
changes structurally even as their functions are modified by these 
changes. This resilience can be seen in X-ray structures of modified 
proteins and at the functional level in the general observation of additive 
effects in multiply mutated proteins. 143 Using this approach it is possible 
to evaluate the contribution of selected amino acids to both receptor 
binding and biological activity. 
In two recent studies, 144 ' 145 changes were made to the NGF primary 
amino acid sequence by site directed mutagenesis. The mutated 
sequences were cloned in an expression vector followed by transient 
expression in mammalian cells. Subsequent changes to binding and 
biological activity were measured and an assessment made of the 
contribution to the recognition process of the mutated amino acids. 
A second procedure involves the chemical modification of reactive 
amino acid side chains and several studies have been published. 
Conversion of the evolutionary conserved residues Trp 21, 76 and 99 to 
the oxindole derivative using N-bromosuccinimide has been examined. 
The functional importance of these residues still remains unclear due to 
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the contradictory evidence of two studies carried out using this 
procedure. 146,147  Iodination and nitration of the two tyrosine residues of 
NGF appeared to indicate that both of these residues were close to the 
surface but their integrity was not required for activity. 146 Similarly the 
lysine residues were thought to be non-essential as treatment with 
dimethylsuberimidate, 148 acetylation or succinylation 149 showed low 
levels of inactivation. Complete modification of the arginine residues by 
1, -cyclohexanedione resulted in inactivation suggesting a critical role for 
these residues. 149 Although information can be obtained from chemical 
modifications a certain amount of ambiguity in the results must be 
allowed for as gross structural changes may occur using these reagents. 
A third more commonly used approach leading directly to more 
pharmacologically viable products is the truncation of a protein sequence 
to a small peptide capable of recognising the receptor binding site. This 
can be achieved by chemical synthesis and was the strategy selected for 
this study. 
In some cases where the 3-dimensional structure of a receptor is 
known, it may be possible using high-resolution X-ray crystallography to 
determine not only the residues involved in binding but also the 
bioactive conformation of these residues. Similarly two and three-
dimensional NMR methods can now produce high resolution solution 
structures for proteins and protein-ligand complexes. 150 This obviously 
could provide leads for peptide synthesis. 
In the vast majority of cases however the receptor structures are still 
unknown although the primary amino acid sequence may be available. 
Suitable sequences may therefore be chosen on a purely speculative 
basis or by considering the relationships which exist with other known 
sequences and structures. The increase in the number of known 
sequences 15 ' to over 25000 makes the study of homology a perfectly 
viable one. 
In both cases the development of structure activity relationships 
(SARs) is a prime requirement. Identification of key fragments can be 
followed by amino acid substitutions, deletions and insertions into the 
parent sequence. Subsequent SARs can be established by adding 
conformational constraints both global and local, peptide bond isosteres 
or cyclisations. At this point biophysical studies can provide clues into 
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the structural and functional requirements of the receptor and further 
analogue syntheses can enhance the biological effect. 
The general outline for the design of bioactive NGF peptides is given 
in FIG 2.1. 
Protein Primary Structure I 
4, 
I Sequence Dissection. Discovery 
I of the Minimum Functional Unit 1 
Testing Biophysical Methods 
NMR, Computational analysis etc. 
	
I Analogue I 	I Establishment of Structure Activity 
Synthesis Relationships. Elucidation of Residues 
Important for Biological Activity 
Agonist or Antagonist 
FIG 2.1. Schematic representation for the rational design of bioactive peptides. 
In this study peptides were initially selected for synthesis on the basis 
of sequence homologies. NGF activity has been identified in many 
vertebrates including reptiles and the amino acid sequences are now well 
documented. The alignment of mouse, 36 human,38 bovine,39 rat36 and 
chicken39 NGF highlights several regions which appear to have 
remained unchanged during the course of the evolutionary process (FIG 
2.2). 
This apparent resistance to change may be considered to reflect the 
functional importance of the amino acid side-chains contained in these 
regions. These sequences therefore provide initial targets for peptide 
synthesis and for the generation of structure activity relationships. 
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FIG 2.2. Sequence alignment of mouse, human, bovine, rat and chicken NGFs. 
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2.1.2 The Initial Synthetic Programme 
The segments 21-36, 41-59, 66-91 and 95-115 represent the major 
conserved regions on most of the known NGF sequences. With this in 
mind it was decided to synthesise the entirely conserved regions of> 5 
residues. These peptides were synthesised using the method of solid 
phase peptide synthesis previously discussed and their sequences are 
listed in Table 3. 
Amino Acid Sequence 
	 Compound Nos. 
10-17 	GEFSVCDS 152 
21-36 WVGDKTTATDIKGKEV 19 
41-46 EVNINN 20 
50-60 KQYFFETKCRD152 - 
66-72 SGCRGID 21 
74-91 KHWNSYCTTTHTFVKALT 22 
95-120 KQAAWRFIRIDTACVCVLS 23 
RKAVRRA 
IdLIIV .Y 
In 1980 Sabesan 153 published a paper which detailed the existence of 
homologies between Insulin and NGF at the secondary structural level. 
Using the predictive algorithm developed by Chou and Fasman,154 
significant homologies were identified between NGF and the B-chain of 
proinsulin which was known to contain the active site region. 155 This 
sequence identified as B22-B26 contains the residues RGFFY and was 
thought to be responsible for receptor binding and biological activity. It 
was noted that NGF had a similar row of three aromatic residues 
contained in the sequence 50-54 (KQYYF) which closely resembled the 
insulin active site. Sabesan also showed that alignment of these 
homologous active site regions appeared to superimpose the secondary 
structural pattern of the B-chain and the C-peptide on that of NGF 25-80. 
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Since NGF has been shown to exhibit many insulin like activities with 
sympathetic neurons 156157 it was decided to synthesise the peptides 50-
54, 46-54 and 25-54 (Table 4). 
The apparent inactivation of NGF after chemical modification of the 
seven arginine residues in mouse NGF (50, 59, 69, 100, 103, 114, 118) 
made this an interesting area for further investigation and so several 
peptides containing these residues were selected for synthesis. Residue 
50, although non conserved across the species, was present as a lysine in 
the human sequence 25-54; 100, 103, 114 and 118 were all incorporated 
in 95-120. The remaining two arginines were included in sequences 59-
67 and 66-79. 
Several other peptides from the N-terminal third of the protein were 
also included in the initial synthetic programme. These are listed in 
Table 4. 
Amino Acid Sequence 	 Compound Nos. 
50-54 KQYFF 24 
46-54 NSVFKQYFF 25 
25-54 KTTATDIKGKEVMVLGEV 26 
NINNSVFKQYFF 
59-67 RDPNPVDSG 27 
66-79 SGCRGIDSKHWNSY152 - 
95-120 KQAAWRFIRIDTACVCVLS 23 
RKAVRRA 
15-23 CDSVSVWVG 28 
34-42 KEVMVLGEV 29 
14-28 VCDSVSVWVGDKTTA-NH2 30 
14-28 Ac-VCDSVSVWVGDKTTA-NH2 31 
14-28 VSDSVSVWVGDKTTA-NH2 32 
14-28 Ac-VSDSVSVWVGDKTTNH2 33 
Table 4 
These peptides were then tested by our collaborators Parke Davis and 
Chiron in the NGF receptor binding assay. 
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2.2 The NGF-Receptor Binding Assay 158 
At the inception of this project the understanding was that the NGF 
receptor was the product of a single gene. 159 The gp75NGFR  was thought 
to be the only receptor required for high affinity binding and signal 
transduction. The resulting biological responses were believed to be 
triggered by the internalisation of the protein-receptor complex. 160 
Retrograde transport of this complex to the nucleus was then thought to 
initiate protein synthesis through a second receptor located on the 
nuclear membrane or on the chromatin. 161 
The establishment of this assay therefore reflects the knowledge of the 
NGF receptor system as it existed at the beginning of this project. Since 
the recent discovery of trk and its signal transducing cytoplasmic 
domain, attempts are being made to develop a functional assay for this 
new receptor by our collaborators. This however detracts in no way from 
the obvious importance of the gp75NGFR  which has already been shown 
to be critically involved in high affinity binding. This receptor also binds 
other members of the neurotrophin family of proteins with a similar 
affinity. These proteins serve to maintain the function of a variety of cell 
types found to degenerate in a range of neurological diseases. 
Information on gp75NGFR may therefore provide leads in other areas. 
Our collaborators initially developed a cell based system for the early 
NGF assays. This was found to suffer from problems with 
reproducibility. Cells known to express gp75NGFR  were coated onto 
microtitre plates and used in competitive binding studies. In this case 
however the cells became detached from the plates in the presence of 
some of the compounds being assayed. Fixing the cells with 
formaldehyde to the assay plates only resulted in an increase in non 
specific binding and inconsistent results. 
These problems were overcome by using the technique of gene cloning. 
Our collaborators at Chiron produced several mammalian cell lines 
capable of secreting milligram quantities of human NGF-receptor. 
Chinese hamster ovary cells (CHO) were transfected with an expression 
plasmid containing cDNA fragments. Clones secreting NGF-receptor 
were detected by chasing experiments using 35S labelled cysteine and 
incorporation of the marker into protein was detected by 
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immunoprecipitation with an NGF-receptor antibody followed by 
electrophoresis and autoradiography. 
Biochemical characterisation of one cloned receptor product showed 
that it contained the first 222 amino acids of the extracellular domain of 
the gp75NGFR protein. This recombinant product was shown to bind 
mouse 1251...NGF in an inhibition study. It was therefore chosen to 
establish a competitive binding assay to assess the ability of our peptides 
to inhibit mouse 1251..NGF  binding. 
The recombinant receptor was anchored to the wells of microtitre 
plates using two methods. In early experiments the receptor was 
immobilised using an antibody termed R2. This method suffered from 
the dissociation of the receptor during the assay and also from, what is 
assumed to be, a steric effect of the antibody which hindered binding of 
NGF to the receptor. The NGFR2 assay was later replaced with a biotin 
anchor. This assay utilised the high affinity of biotin for the protein 
streptavidin. Biotinylation of the recombinant receptor followed by 
incubation in streptavidin coated wells provided a much improved 
anchor. Incubation for 2 hours, of 1251...NGF  with a 100 .tM solution of 
peptide dissolved in dimethylsuiphoxide (DMSO) was followed by a 
careful wash cycle and then an assessment of the binding ability of each 
test peptide was made. Competition for the receptor by the peptide 
results in a decrease in the measured counts per minute as increased 
quantities of unbound 1251..NGF are removed during the final wash cycle 
(FIG 2.3). 
= Streptavidin 
Biotin e 	<C> = (ID I 	= Recombinant receptor 
= Test peptide 
FIG 2.3. The NGF competitive binding assay. The peptide competes with 
radiolabelled 1251-NGF for binding sites on the receptor. 
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2.3 The NGF Binding Assay Results 
The results from the assays of the first selection of peptides are 
summarised below in Table 5. 
% Inhibition 
Amino Acid Sequence 	 R2 @100 gM 	Biotin @ 100 p.M 
10-17 GEFSVCDS 0 	 - 
21-36 WVGDKTFATDIKGKEV 6 	 - 
41-46 EVNINN 16 	 - 
50-60 KQYFFETKCRD 16 	 - 
66-72 SGCRGII) 15 	 - 
74-91 KHWNSYCTFHTFVKALT 0 	 - 
95-120 KOAAWRFIRIDTACVCVLSRKAVRRA IM 
50-54 KQYFF 2 	 0 
46-54 NSVFKQYFF 0 	 - 
25-54 KTTATDIKGKEVMVLGEVNINNSVFKQYFF 19 	 21 
59-67 RDPNPVDSG 0 	 - 
15-23 CDSVSVWVG 0 	 - 
34-42 KEVMVLGEV 2 	 - 
14-28 VCDSVSVWVGDKTFA-N112 19 - 
14-28 Ac-VCDSVSVWVGDKT1'A-NH 2 14 	 - 
14-28 VSDSVSVWVGDK11A-NH2 25 	 - 
14-28 Ac-VSDSVSVWVGDKTIA-NH2 15 	 - 
Table S 
These results clearly indicate the inhibition of 1251-NGF binding to the 
recombinant receptor by the C-terminal sequence 95-120 (23). At a 
concentration of 100 gM this peptide shows a percentage inhibition of 
80% in the NGFR2 assay and 88% in the biotin assay. This represents a 
considerable level of binding and demonstrates a major contribution to 




2.4 Optimisation of hNGF Lead 95-120 
At this point after the synthesis of hNGF 95-120 two divergent 
approaches were considered for the development of this lead. A larger 
fragment of the C-terminal region may possess enhanced binding if more 
functional residues are present. If such a peptide showed no significant 
increase in binding efficiency we may conclude that the sequence 95-
120 contains a high proportion of the amino acids required for binding to 
the receptor. The next logical step would then be to examine shorter 
sequences than hNGF 95-120 to find the minimum unit which retains a 
significant amount of binding. 
With this in mind it was decided to synthesise the C-terminal third of 
human NGF between residues 81-120. 




The synthesis of hNGF 81-120 was carried out using an ABI 430 
peptide synthesiser with triple couple cycles (FIG 2.4a). Starting with 
1.0 g of lightly loaded Wang resin (0.27 mmolg') it was possible to 
drive most of the coupling reactions to completion as was evinced by the 
deprotection profile which dropped by approximately 10% over the 
length of the sequence (FIG 2.4b). Incorporation of the trityl derivative 
of cysteine meant that cleavage of the peptide from the resin in TFA 
containing scavengers gave the crude product in the dithiol form. The 
hplc profile of this material is shown in (FIG 2.4c). This material was 
readily purified to a homogeneous product by preparative reverse phase 
hplc (FIG 2.4d). 
During this purification it was observed that solutions of the purified 
product slowly became contaminated with a compound which was 
reasoned to be the disulphide from the oxidation of the cysteine residues. 
As expected addition of acetic acid considerably slowed this reaction 
down. It has also been found possible to completely convert the pure 
dithiol peptide to a single oxidised form in 1-2 days in 0.1% TFA in 
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water (FIG 2.5a) and in 1-2 hours when oxidised with potassium 
ferricyanide, K3Fe(CN)6. The addition to a solution of the oxidised 
peptide of dithiothreitol (DTT) reversed this process. When the oxidation 
was allowed to proceed in more concentrated solutions (20 mg/ ml) the 
hplc traces of these oxidations showed an increase in the amount of 
retained hydrophobic material indicating polymerisation. Further 
examination of the oxidised product from dilute solutions by fast atom 
bombardment mass spectroscopy (FABMS) showed no sign of these 
dimers or higher polymers and so it appeared that the disulphide formed 
was the intramolecular one (FIG 2.5b). 
Triple Couple Cycle Nos. Activated Amino Acid 	Coupling Time 
1 	 Symmetrical Anhydride 1/2 hour 
2 HOBt Ester 	 1/2 hour 
3 	 HOBt Ester 1/2 hour 







120 	 80 
Amino Acid Sequence 
FIG 2.4b. Monitoring of the Fmoc/ Piperidine adduct at 302 nm. 
d 
FIG 2.4. HpIc traces of the crude (c) and purified product (d). 
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t 	 t=3 	t=6 	 t=27hours 
FIG 2.5a. Oxidation of fragment 81-120 in Ca. 0.5 mM solution (distilled 
water). The solution was analysed under identical conditions by hplc at t =0, t 
=3, t =6 and t =27 hours. The column conditions were Aquapore RP 300 (20 cm 
X 0.4 cm), 7 micron, C18; gradient 10-60% CH 3CN over 20 mm. using 
solutions A = 0.1% TFA/ H20, B = 0.1% TFA/ CH3CN; flow rate = 1 ml/ mm.; 








5080 	4508 	4000 	3500 
FIG 2.5b. Fast Atom Bombardment Spectra of peptide hNGF 81-120 oxidised. 
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2.4.2 Comparison of 95-120 (23') and 81-120 (34') in the NGF Receptor 
Assay 
A direct comparison of both these peptides in the receptor binding 
assay showed that at a concentration of 100 jiM, 81-120 inhibited 1251.. 
NGF binding slightly better than 95-120. At this point however, it was 
unclear whether this difference was a significant one (Table 6). 
In order to evaluate and compare the binding activities of the dithiol 
peptides with that of the observed oxidised form, two sets of assays were 
performed. The reduced peptides were examined in the assay in the 
presence of the reducing agent 2-mercaptoethanol, while the oxidised 
form was tested in its absence. The results showed that the free reduced 
dithiol peptides bind with lower affinity to the receptor. The significance 
of this drop once again had to be questioned. The NGF-receptor contains 
multiple disulphide bridges which may have a significant role to play in 
the stabilisation of the binding site structure. Any disruption to these 
bridges would almost certainly have reduced the observed figure for the 
inhibition of 1251..NGF binding. 
An alternative hypothesis is also worthy of consideration. The 
formation of the disulphide bridge introduces to this peptide a local 
structural constraint which may have the effect of stabilising a mimic of 
the bioactive conformation around the residues ACVCV. 
In order to remove these ambiguities from future results peptides 
containing Cys 108 and Cys 110 were prepared in the oxidised form. 
Sequence 
	 %Inhibition at 100 jIM 
95-120 	 oxidised 	 88 
reduced 80 
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By repeating the assay at several different peptide concentrations and 
plotting % inhibition against concentration a dose response curve was 
obtained. 
From this graph it was possible by extrapolation to determine the 
concentration of peptide which produced a 50% inhibition of 1251...NGF 
binding in the assay. This figure, known as the IC 50, provides a more 
accurate comparison of the peptides under test. The initial dose response 













FIG 2.6. The dose response curve for 95-120 and 81-120. 
From this graph it was clear that both sequences had an IC 50 of 
approximately 15 j.tM. The apparent lack of improved binding by the 
longer sequence may simply represent the fact that all the amino acids 
required for the receptor interaction are already contained in the 
sequence 95-120. 
Subsequent improvements to the assay system later produced a figure 
of 1 iM for the IC 50  of peptide 81-120. The sequence 95-120 has not 




2.4.3 Determination of the Shortest Functional Unit 
In an effort to decipher the shortest peptide capable of inhibition of 
1251..NGF binding the following series of overlapping peptides were 
synthesised (Table 7). Peptides were tested in the oxidised form and in 
the Biotin assay unless otherwise stated. 
Amino Acid Sequence 
	 %Inh. 	IC50 Comp. 
@100 tM (j.LM) Number 
88 	15 	23 
92 15 - 
18 	- 	35 
31 - 36 
20 	- 	- 







111-116 	 VLSRKA152 
Table 7 
From this information it was clear to see that residues 117-120 were 
not essential for the binding interaction and so these residues could be 
excluded from future syntheses. None of the other peptides listed above 
showed significant levels of inhibition and so a further series of longer 
peptides were prepared (Table 8). 




100-115 RFIRIDTACVCVLSRK 152 
100-114 RFIRIDTACVCVLSR 152 
100-113 RFIRIDTACVCVLS 
101-115 FRIDTACVCVLSRK152 
% Inh. 	IC50 Comp. 
@3Oor1OOzM 	(.tM) Number 
95@100 10 	37 
90@100 8 38 
92@100 3 	39 
84@100 12 - 
- 3 	- 
23@30 - 	 40 
31@30 - 	 - 
Table 8 
As the sequence was shortened from the N-terminus no apparent loss 
of binding was observed until the residue Arg 100 was removed. This 
residue appears to be involved therefore in the receptor binding 
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interaction. A similar picture emerged when the sequence was shortened 
from the C-terminus. Binding was dramatically reduced when Arg 114 
was removed from the peptide. 
The shortest fragment exhibiting significant inhibition was therefore 
100-114. This 15 residue peptide had an IC 50 value of around 3 j.tM 
which was comparable to that of peptide 81-120 (1 jiM). 
2.4.4 Sequence Comparison of NGF 100-114 with the Neurotrophin 
Family 
The sequence 100-11.4 of NGF is a region which shows high 
homology with the other members of the neurotrophin family of 
proteins. By careful analysis and exploitation of the similarities and 
differences which exist between these sequences it may be possible to 
determine other active site residues. This information may help to 
evaluate further the criteria for binding to gp75.NGFR  
Several peptides were synthesised corresponding to the region 100-116 
of these proteins and the IC 50 values are summarised in Table 9. 
Amino Acid Sequence IC50 	Compound 
(pM) Number 
m, h, c NGF 	100-116 RFIRIDTACVCVLSRKA 8 	38 
bNGF 100-116 RFIRIDTACVCVLSRKT 
b, mNF 100-116 RFIRIDTSCVCTLTIKR 5 	41 
m NT3 100-116 RWIRIDTSCVCALSRKI' 52 13 - 
Analogue 100-116 RFIRIDTSCVCVLSRKA 152 12 	- 
Table 9. Amino acid differences shown in bold type. 
The homology study shows that most of the amino acid changes occur 
towards the C-terminal portion of these sequences. There appears to be a 
range of allowable substitutions at position 111 with the residues Val, 
Thr and Ala being tolerated with the apparent retention of binding. The 
replacement of Ala 107 with Ser does not appear to significantly alter 
the IC50  value nor does the incorporation of Trp instead of Phe at 
position 101. Position 116 appears to be the least conserved with Ala, 
Thr, Arg and Tie all being tolerated at this position. It was not surprising 
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therefore that residues 116 and 115 could be removed without a drop in 
the observed IC50 value. 
The pattern of allowable changes and the obvious high homology of 
some residues provides further evidence for the elucidation of the amino 
acids involved in binding. A consensus recognition sequence for these 
critical binding residues is shown in FIG 2.7. 
FIG 2.7. The consensus recognition sequence 
for the sequence hNGF 100-114. 
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2.5 The NGF X-Ray Structure and Consensus Sequence Comparison 
Towards the end of 1991 Blundell et al. 162 published the crystal 
structure of murine NGF dimer at a resolution of 2.3 L It showed that 
NGF consists of seven [3-strands which contribute to the formation of 
three antiparallel pairs of [3-strands. Twists in these structures and the 
contribution made by the three disulphide bridges allows for the 
formation of a hydrophobic core. 
Fig 2.8 shows the [3-strand structure of NGF, starting at the N-terminus 
they are labelled A (residues 15-22), A' (residues 27-30), A" (residues 
35-38), A" (residues 40-44), B (residues 47-59), C (residues 79-93) and 
D (residues 96-111). Strands A and A" form hydrogen bonds with B 
while strand A' and A" form a double-stranded [3-sheet. Strand C forms 
hydrogen bonds with D to form an antiparallel and very twisted [3-sheet. 
FIG 2.8. The f3-strand structure of NGF. 
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Several regions were poorly determined in the X-ray analysis of NGF. 
No density was observed for the residues 1-10 (the amino terminus) and 
the residues 112-118 (the carboxy terminus). Both these regions were 
therefore believed to be highly flexible and solvent accessible. It was 
interesting to note that the fragment 112-118 contains the amino acids 
Ser 113 and Arg 114 which were found to be essential for inhibition of 
125I...NGF binding in the receptor assay. 
Using the molecular graphics programme SYBYL it was possible to 
add Ser 113 and Arg 114 and view the consensus recognition sequence 
(CRS) as it exists in the native protein (shown in yellow Plate 1). It can 
clearly be seen that the CRS is contained in the [i-strand designated D 
(residues 96-111) and that most of the residues appear to be readily 
accessible and available for interaction with the receptor. 
It was also observed from the sequence alignment of the other 
members of the neurotrophin family that most of the conserved residues 
were confined to these n-strand regions. This suggests that the same 
overall three dimensional structure is adopted by this family of proteins. 
A similar study of the n-hairpin loops which link regions A' to A", B to 
A" and D to C and the reverse turn contained in residues 59-66 showed 
that around 75% of variable residues occur in these areas of the protein. 
These regions may therefore form part of the receptor binding 
determinant involved in the highly specific interaction with the various 
forms of the trk receptor (trk, trkB, trkC). 
One of these loops (92-98) is contained in the peptide 81-120. The 
computer graphics representation of part of this sequence (81-99), as it 
occurs in the protein is coloured green and is shown in plate 1. It can be 
seen that this peptide contains the major twisted p-sheet structure of 
strands C and D. 
In a recent publication, 145 reduced levels of binding to the low affinity 
gp75NGFR were noted when site directed mutants of NGF were prepared 
incorporating Ala in place of Lys 32, Lys 34, and Lys 95. Simultaneous 
modification of Lys 32 with either of the other two lysines resulted in the 
loss of binding to gp75NGFR implicating these three basic residues in 
receptor binding. These three residues along with Arg 100, 103, 114 Arg 
118 and Lys 115 are coloured magenta in plate 1. It is interesting to note 
the close proximity of these lysine residues to Arg 100 and 103 at the N-




positively charged unit involved in binding to the acidic gp75.NGFR  The 
absence of the C-terminal region of the protein from the X-ray data due 
to its high flexibility means that Arg 114, 118 and Lys 115 may also 
have a critical role to play in the recognition process. 
Plate 1. The hNGF protein showing the CRS (yellow), the 
sequence 81-120 (green) and the basic residues (magenta) thought 
to be involved in the receptor recognition process 
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2.6 Investigation of the Functional Importance of the Disulphide 
The observation that peptides 95-120 (23) and 81-120 (34) 
demonstrate lower levels of 1251-NGF binding inhibition when tested in 
the assay under reducing conditions has already been discussed. When a 
similar comparison was made between the oxidised and reduced form of 
the peptide hNGF 100-116 (38) a significant difference was found with 
the oxidised form showing much higher affinity and consequently a 
lower IC50 value (Table 10). 
Sequence Assay %Inh. @100 j.iM IC50 
100-116 oxidised 90 10 .tM 
100-116 reduced 30 >100 p.M 
Table 10 
The high degree of flexibility of the dithiol peptide means that in 
solution this peptide interconverts between conformations and so at 
equilibrium, exists in many different structural forms. However, when 
associated with the receptor, it is unlikely that it can adopt more than a 
single conformation. The issue seems to be which solution structure best 
approximates the receptor-bound conformation. Assuming a 'lock and 
key' mechanism for the interaction, it might be expected that only one of 
the solution conformations will approximate the receptor bound 
structure. On the other hand, an induced fit or 'zipper' mechanism 
assumes that the ligand adopts the correct conformation whilst 
interacting with the receptor. In either case the formation of a 13 
disulphide in these peptides represents a significant restriction to the 
conformational freedom around the cysteine residues. This structural 
change within the peptide may afford an analogue in which many of the 
conformational alternatives have been precluded. The introduction of a 
similar disulphide into the linear octapeptide angiotensin II has been 
shown to produce a series of highly potent cyclic analogues. 163 
It may be appropriate to interpret the dramatically increased activity of 
the oxidised peptides in these assays as being the result of an increase in 
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the effectiveness of the interaction of the restrained analogue with the 
receptor. Although the conformational constraint imposed may not 
influence the whole sequence, the oxidised peptide is, relative to the 
acyclic analogue, still quite constrained at those residues which are 
endocyclic. This steric crowding provides insights into the structure of 
the biologically active state of this portion of the molecule. 
The presence of a 1,3 disulphide in experimental peptides has been 
shown to fulfil the requirements of an ideal y-tum conformation 
stabilised by the formation of two intramolecular hydrogen bonds (FIG 
2.9). 164 These bonds exist between the NH of the residue i and the 
carbonyl of residue i+2 (1 to 3, C 11 ) and the carbonyl of residue i and the 
NH of residue i+2 (3 to 7, C7). The occurrence of a y-tum conformation 
in these peptides possessing an 11- membered loop may have a 
significant role to play in their activity. 
HO 
i+2 
7_H O \ 
FIG 2.9. They-turn conformation. 
Several peptides were chosen for synthesis to assess the role of the 
amino acids around the sequence containing the disulphide (ACVCV). 
Firstly the hypothesis was made that perhaps the oxidised form of the 
peptide was undergoing disulphide interchange with the receptor. The 
gp75NGFR has been shown to contain a large number of disulphide 
bridges which link four cysteine rich repeat sequences. 
Recently Lawrence et al. 165 published a paper which describes a 
peptide-based enzyme inhibitor containing a reactive 1,2 disulphide. The 
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intramolecular disulphide is a potent electrophile and appears to take 
part in disulphide exchange with the protein A-kinase resulting in its 
rapid inactivation. Theoretical 166 studies indicate that the formation of 
the 1,2 disulphide requires a cis peptide bond between the cysteine 
residues. 
A similar mechanism of action could be proposed for the increased 
binding observed in the oxidised forms of the NGF peptides (FIG 2.10). 
It was therefore decided to synthesise hNGF 100-115 (42) with the 
removal of Val 109 and the inclusion of the 1,2 disulphide bridge. 
Arg.Phe.I!e.Arg.Ile.Asp.Thr.Ala.Cys.Cys.Val .Leu.Ser.Arg.Lys (42) 




- Cys - Receptor 	 SH 




0 	 S - Cys Receptor 
FIG 2.10. Hypothetical mechanism for receptor binding. 
The synthesis of this peptide was carried out on the ABI 430 peptide 
synthesiser using standard double couple cycles. Starting with 1.0 g of 
'Wang' resin loaded with 0.51 mmo!g-1 of lysine, the peptide was 
synthesised with no major assembly problems as was evinced by the 
deprotection profile. Cleavage of the resin and purification of the crude 
product by reverse-phase hplc resulted in a reasonable yield of 
homogeneous product. The choice of trityl protection for both cysteine 
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residues meant that the purified product was isolated in the reduced thiol 
form. 
Air oxidation of a 30 iM solution of the dithiol peptide in distilled 
water showed that the reaction was very slow. The oxidation was 
monitored by analytical hplc and found to be complete after a period of 
14 days. This was compared to 2-3 days for oxidation of the 1,3 dithiol 
peptides and reflects the unfavourable nature of the cis peptide bond and 
strained 8 membered ring system. 
By incorporating into the sequence hNGF 100-114 the more hindered 
P-dimethyl substituted residue L-penicillamine, the effect of increased 
steric bulk to the disulphide was evaluated. This substitution also 
increased the hydrophobic nature of the ring system. 
Arg.Phe.Ile.Arg.Ile.Asp.Thr.Ala.Pen.Val.Pen.Val.Leu.Ser.Arg(43) 
Fmoc-L-penicillamine was prepared as the acetamidomethyl (Acm) 
protected derivative using the synthesis outlined in FIG 2.11. 
L-Penicillamine (1 eq.) (44) and N-hydroxyacetamide (1.2 eq.) (45) 
were firstly dissolved in a 10% solution of TFA in water. The mixture 
was stirred in an ice-bath and trifluoromethanesulphonic acid (TFMSA) 
in TFA (1:19) was added with stirring under argon. The reaction was 
monitored by TLC and was found to be complete after 90 minutes. The 
solvent was removed in vacuo to give an oil. To this was added a 10% 
solution of sodium carbonate until the pH had risen to 10. The solution 
was once again stirred in an ice-bath and Fmoc succinimide (Fmoc-
ONSU), dissolved in an equal volume of dioxan, added dropwise over a 
period of 30 minutes. The mixture was allowed to stir at room 
temperature for 2 days. After extraction with ether, acidification to pH 2 
and extraction into ethyl acetate, 7.5 g of product (46) was isolated in the 
form of a foam after evaporation. The product was purified by dissolving 
in hot dichioromethane and adding hexane to incipient turbidity. This 
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FIG 2.11. The synthesis of Fmoc-L-Pen(Acm)OH. 
Starting with 0.5 g of resin loaded with 0.49 mmolg -1 of Fmoc-
Arg(Pmc), the peptide was assembled in the ABI 430 peptide synthesiser 
using standard double couple cycles. Initial attempts at coupling the 
protected penicillamine derivative using these cycles failed. This was 
demonstrated by a drop in the deprotection profile of around 80%. 
Studies then showed that levels of incorporation could be greatly 
increased by using 3 equivalents of symmetrical anhydride at 50 0C with 
sonication for a period of 2 hours. The residues Pen 108, Val 109 and 
Pen 110 were all coupled in this manner. The remaining residues were 
coupled manually in the bubbler apparatus detailed in Appendix I. 
Cleavage of the peptide in TFA containing scavengers and purification 
of the crude product by reverse phase hplc led to a good yield of 
homogeneous Acm protected peptide. 
Attempts were made to remove these protecting groups using the 
method of Fuji et al. 133 The peptide was treated with silver 
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trifluoromethanesuiphonate (AgOTf, 5 eq.) in TFA containing anisole (2 
eq.) at 0°C for 60 minutes. This resulted in the formation of the peptide 
silver salt and could be monitored by analytical hplc. After evaporation 
of the TFA in vacuo the silver salt was precipitated and triturated several 
times with ether and air dried. It was then treated with dithiothreitol 
(DTT, 80 eq.) in 50% acetic acid. The regenerated dithiol peptide should 
have been the final product of this procedure but analytical hplc still 
showed the presence of silver salt. 
A second procedure also documented by Fuji et al. 135 was then 
attempted. This method used thallium(ffl) trifluoroacetate in TFA to 
cleave the Acm protecting groups and had the added benefit of 
simultaneous disulphide bond formation. The mechanism proposed for 
this cleavage and oxidation is shown in FIG 2.12. 
Aan—S 	S-Acm 
+ 	I I 
CF3GO0 H3N- - - Pen .VALPen - - - OOH 
(CF3COO)3T1 + 
)OCCF3 $ 
CF,C 00 —TI, 
S 	S-Acm 
+ 	I I 	 Acrn 	+ CF3COO 
H3 N• - -- - Pen .VAL.Pen - - - COOH 
CF3COO 	
OOCCF3 
+ 	 + 




+ 	I I 
C F3COO H3  N- - - - Pen .VAL.Pen - - - COOH + 
FIG 2.12. Cleavage and disulphide formation using TI(III) trifluoroacetate. 
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The protected peptide was dissolved in TFA and treated with 1.2 
equivalents of (CF3COO)3T1 in the presence of anisole and in an ice-bath 
for 60 minutes. The TFA was then evaporated in vacuo and the resulting 
powder was dissolved in 20% aqueous acetic acid (5 ml). The peptide 
solution was then passed down a Sephadex G25 gel filtration column 
and the peptide fractions collected and freeze-dried. 
The final product differed from the starting material on analytical hplc 
and was confirmed to be the oxidised form by FABMS, amino acid 
analysis and by the observation of a negative Eliman's test for free 
thiols. 167"68 
A third peptide was selected for synthesis on the basis of introducing a 
further conformational constraint to the sequence ACVCV. This peptide 
contained the residue a-aminoisobutyric acid (Aib) as a direct 
replacement for Ala 107. 
Arg.Phe.Ile.Arg.Ile.Asp.Thr.Aib .Cys.Val .Cys.Val.Leu.Ser.Arg (47) 
The peptide bond generally adopts a trans conformation and deviates 
only slightly from planarity. 169 This leaves only two angles which need 
to be considered to define the backbone configuration of a peptide. 
These are , which defines the angle about the Na-Ca bond and P, 









By replacing the hydrogen at the a-carbon with a methyl group to give 
a dialkyl amino acid it is possible to reduce considerably the 
conformational space allowable for rotation around these bonds. This is 
due to the unfavourable overlap of neighbouring atoms. 
The peptide (47) was synthesised as before on the ABI 430 peptide 
synthesiser, however under normal conditions poor coupling was 
observed for the Aib residue. This amino acid was therefore coupled 
manually with sonication at 500C. The cysteine residues were coupled 
using S-t-butyl suiphenyl protection. After an initial purification step 
using reverse-phase hplc, these groups were removed in trifluoroethanol 
('iFE) in the presence of several equivalents of tributylphosphine to give 
the dithiol peptide. 136 Oxidation of this peptide was carried out using a 
10% solution of dimethylsulphoxide (DMSO) in TFA. 140  
2.6.1 Structure Activity Relationship of Cys Modified Peptides 
The three cysteine modified peptides were tested in the NGFR binding 
assay and the results are summarised in Table 11. 
Amino Acid Sequence % Inhibition iM 
100-116 RFIRIDTACVCVLSRKA Oxidised 90 @ 100 
100-116 RFIRIDTACVCVLSRKA Reduced 30 @ 100 
100-115 RFIRIDTACCVLSRK Oxidised 24 @ 100 
100-115 RFIRIDTACCVLSRK Reduced 28 @ 100 
100-114 RFIRIDTAPenVPenVLSR Oxidised -24 @ 10 
100-114 RFIRIDTAPenVPenVLSR Di-Acm protected 	-26 @ 10 
100-114 RFIRIDTA1bCVCVLSR Oxidised 70 @ 10 
Table 11 
It is apparent from the above results that one of the requirements for 
activity in these peptides is the 1,3 disulphide. Removal of Val 109 and 
formation of the 1,2 disulphide completely inactivates the peptide in 
both the reduced and oxidised form. Increasing the hydrophobic nature 
of the disulphide by introducing the ,f-disubstituted amino acid L-
penicillamine also has a detrimental effect on binding. 
Both these results seem to emphasise the importance of the ACVCV 
region in the binding interaction. The introduction of Aib to this 
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sequence does appear to be an allowable change although the IC 50 value 
has not yet been determined. 
2.6.2 Global Constraints 
The incorporation of Aib and the 1,3 disulphide while introducing 
local constraints, still does not constitute a stable rigid structure. In order 
to define a 'template' for the biologically active conformation of these 
peptides it may be necessary to introduce a global constraint. 
Using the peptide hNGF 100-114 as the C-terminal amide an attempt 
was made to form the lactam bridge between the N-terminus and the side 
chain of Asp 105. Oxidation of the cysteine residues would then result in 
a bicyclic peptide incorporating a considerable number of constraints. 
To a 40 .tM solution of this peptide in distilled DMF was added 
diphenylphosphorylazide' 70  (DPPA, 2 eq.) and triethylamine (TEA, 2 
eq.) with stirring at 0°C. The reaction mixture was allowed to warm to 
room temperature over a period of several hours. 
The cyclisation was followed by analytical hplc. The starting material 
appeared to be significantly modified after a period of 10 days. The 
mixture was therefore evaporated leaving an oil which was dissolved in 
20% acetic acid solution and extracted several times with diethyl ether. 
The peptide solution was then purified by preparative reverse phase hplc 
and two major products were collected (FIG 2.14). Analysis by FABMS 
showed that peak 1 contained mainly unreacted starting material while 






The overall low yield of this cyclised product meant that insufficient 
product remained to attempt the disulphide , bond forming step. The 
peptide was therefore tested in the di-Acm protected form. The results 
are shown in Table 12. 
Amino Acid Sequence 	 % Inh. or ICJ 
100-114 RFIRIDTACVCVLSR Di-Acm (cyclic)(48) 	4% @ 10 iM 
100-114 RFIRIDTACVCVLSR Di-Acm protected (acyclic) 	9% @ 10 .tM 
100-114 RFIRIDTACVCVLSR Oxidised-acyclic 	 3 tM IC50 
Table 12 
Testing of the di-Acm protected acyclic peptide along with the lactam 
bridged peptide shows that the effect of the protecting groups has a 
major effect on receptor binding. The apparent lack of tolerance of the 
Acm groups on these peptides further demonstrates the critical nature of 
the sequence ACVCV in the binding interaction. It may be considered an 
objective of future work to prepare enough of the cyclic lactam bridged 




2.7 NMR Studies on C-terminal Peptides 
2.7.1 Introduction 
Nuclear magnetic resonance spectroscopy (NMR) has emerged in 
recent years as a powerful method for the determination of three-
dimensional structures of small proteins and peptides. The sequential 
assignment of the 1H...NMR spectrum of a peptide requires at least two 
types of experiment. Firstly those which demonstrate through bond 
connectivities and secondly those demonstrating through-space (<5 A) 
interactions. 
Through-bond connectivities can be displayed by a large number of 2-
D NMR experiments. The simplest correlation experiment is 
homonuclear 2-D correlation spectroscopy (COSY). This experiment 
permits the grouping of resonances belonging to individual spin systems 
characteristic of the amino acids (FIG 2.15). Some spin classes have 
only one amino acid so that the actual residue can be readily identified. 
This is the case for Gly, Ala, Val, Thr, Leu, Ile and Lys. In other cases a 
particular class may contain several amino acids. Thus Asp, Ser, Asn, 
Cys, and the aliphatic protons of His, Phe, Tyr and Trp all belong to the 






Experiments which only demonstrate direct through bond 
connectivities are of little value if taken alone, owing to problems of 
spectral overlap. Thus as one progresses from the NH and Ca-H protons 
to the side-chain protons the spectral overlap increases. For this reason, 
experiments which also demonstrate indirect through bond connectivities 
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are invaluable. In this respect the Total Correlation Spectroscopy 
(TOCSY) experiment is particularly versatile. Thus for a residue which 
has NH, Ca-H, C-H and Cy-H protons connectivities will be seen 
between all the protons (FIG 2.16). 
H3\ ,CH3 
PCH 
FIG 2.16. NH connectivities. 
Once the spin systems have been identified and the protons assigned, 
sequential through space connectivities involving the NH, Ca-H and C-
H protons can be made by means of 2-dimensional experiments, for 
example Nuclear Overhauser Enhancement Spectroscopy (NOESY) or 
Rotating Frame Enhancement Spectroscopy (ROESY). Some of the 
important connectivities are shown in FIG 2.17. 
H2 
N C- N - - Ir N - C- Ti- 
0 H H 0 H H 0 H H 0 
FIG 2.17. Schematic illustration of sequential NOESY connectivities 
involving NH, Ca-H, and C-H protons of residue i in a polypeptide. 
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2.7.2 Interpretation of the 2-D NMR Spectra of hNGF Peptides 
Of the several NGF peptides studied by NMR the peptide hNGF 100-
115 des-Val 109 (42) has been selected as an example for discussion. 
Arg.Phe.Ile.Arg.Ile.Asp.Thr.Ala.Cys.Cys .Val.Leu. Ser.Arg.Lys (42) 
The stability in solution of the 1,2 in relation to the 1,3 dithiol 
compound means that a comparison can be made between the oxidised 
and reduced forms of this peptide. All the other peptides have been 
studied in the oxidised form using the same experimental conditions. 
Firstly the COSY spectrum was obtained in 90% H 20/ D20 and from 
this it is possible to assign several of the amino acids in the peptide. By 
looking at the contour plot it was possible to identify the characteristic 
pattern of several amino acids. This is illustrated in FIG 2.18 which 
shows the assignment of Val 111. Although this Val residue can be 
unambiguously assigned the same experiment cannot be used to 
determine the sequence positions of the three arginine residues in this 
peptide. Such information can however be obtained from a comparison 
of the TOCSY with the NOESY or ROESY spectra. FIG 2.19 shows part 
of the TOCSY spectrum for this peptide. The vertical lines join each of 
the different spin systems within a given amino acid. It is therefore 
possible to assign all the proton resonances to a given amino acid type. 
Once a full proton assignment has been made an overlay of the TOCSY 
spectrum with the NOESY or ROESY spectrum allows for sequence 
information to be obtained by a procedure known as 'walking the 
backbone'. Starting at the N-terminal CaH (TOCSY) of residue i it 
should be possible to draw a horizontal line to an NH (NOESY) proton 
of residue i+1. This in turn is connected to a TOCSY resonance by a 
vertical line represented by the CaH of residue i+1. For relatively short 
peptides it is often possible to unambiguously assign the proton 
resonances at each position in the sequence. This is shown in FIG 2.20. 
It is often possible from the qualitative interpretation of the sequential 
NOESY or ROESY resonances to determine regular structural elements 
as each type of secondary structure is characterised by a particular 
















4.5 	4.0 	3.5 	3.0 	2.5 	2.0 	i..5 	1.0 
F2 (ppm) 
FIG 2.18. Part of the COSY spectrum of hNGF 100-115 des-Val 111 
The spectrum was run in 90% H 20/ D20 (8 mg/ mI)and shows the assignment 
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FIG 2.19. Part of the TOCSY spectrum of hNGF 100-115 des-Val 109 
The vertical lines join the relayed through bond connectivities of 
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FIG 2.20. An overlay of part the TOCSY and ROESY (90% H2 01 D20) 
spectra of hNGF 100-115 des-Val 109 (dithiol) showing the procedure 
of 'walking the backbone'. 
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A comparison of the reduced and oxidised spectra of the peptide 
shows several differences and, as one might expect, these are most 
significant around the cysteine residues. Table 13 shows the chemical 
shift values for these two residues. 
Chemical shift (ppm) 
Residue NH CczH CI3H 
Cys 108 Reduced 8.29 4.52 2.59, 2.59 
Cys 108 Oxidised 7.65 4.94 3.18, 3.30 
Cys 110 Reduced 8.45 4.58 2.59, 2.59 
Cys 110 Oxidised 7.82 5.04 2.72, 3.38 
Table 13 
On oxidation, the CaH protons experience a deshielding effect relative 
to the free dithiol compound with the consequent downfield movement 
in the observed chemical shift values. This may be due to the proximity 
of these protons in the 8-membered ring to the electrophilic disulphide 
bond. A similar effect is found for the CHs in both cysteine residues. 
The formation of the disulphide also causes significant splitting of these 
protons which are no longer equivalent. 
An opposite effect is observed for the NH chemical shift values which 
appear to drift upfield in the cyclic peptide. The incorporation of these 
protons into the rigid cyclic system may reduce their ability to take part 
in hydrogen bonding. This disruption to important elements of structure 




The observed chemical shift values for the biologically active peptide 
hNGF 100-116 (38) appear to be very similar (Table 14). 
Chemical shift (ppm) 
Residue 	 NH 	CaH 	C3H 
Cys 108 	Oxidised 	7.99 	4.72 	- 
Cys 110 Oxidised 8.13 4.72 - 
Table 14 
The downfield shift observed on oxidation to the 1,3 disulphide moves 
these cysteine resonances into an area of the spectrum close to the water 
suppression signal. This has the effect of considerably reducing the 
intensity of these signals to such an extent that the CaHs and NHs are 
barely detectable and the Cf3Hs are completely obscured. Further 
examination of the NOESY and ROESY data therefore gave no 
structural information on the region containing the disulphide. 
The inter-residue cross peaks found in all the peptides studied by 
NMR were shown to be between neighbouring amino acids. This is 
indicative of a random coil structure and may provide evidence for a 




2.8 D-Amino Acid Scan of the Hydrophobic CRS Residues 
The systematic replacement of L-amino acids by D-amino acids 
provides useful insights into the stereostructural requirements of a 
specific residue for the peptide-receptor interaction. 
It already appears that the charged residues Arg 100, Arg 103 and Arg 
114 and the 1,3 disulphide containing the residues Cys.Val.Cys are key 
elements in the binding interaction. An examination of the three other 
highly conserved hydrophobic residues Ile 102, Ile 104 and Leu 112 by 
direct replacement with their D-amino acids was undertaken. The results 
are summarised in Table 15. 
Amino Acid Sequence % Inhibition Comp. 
Number 
100-114 RFWIDTACVCVJSR 38@10p.M 49 
100-114 RFIRJJDTACVCVLSR 15@10.tM 50 
100-114 RFQIRWTACVCVLSR In Testing 51 
100-116 RFIRIATACVCVLSRKA IC50 24tM 52 
100-114 RFIRIETACVCVLSR 23% @10.tM 53 
Table 15 
The introduction of D-Ile at position 104 seems to have more of a 
detrimental effect on binding than introducing D-Leu at position 112 
although both show a lower level of inhibition than the parent sequence 
(IC50 3 .tM). This may indicate a greater contribution of the Tie residues 
either to the binding interaction or to the stabilisation of a recognised 
bioactive conformation of this peptide. The suggestion from the crystal 
structure is that both lie 102 and Ile 104 form part of the proteins 
hydrophobic core and so would not appear to be available for direct 
interaction with the receptor. The conclusion must therefore be that the 
incorporation of a D-amino acid at position 104 interferes with the 
ability of the peptide to adopt the correct conformation. 
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2.9 Substitution of Asp 105 with Ala and Glu 
The replacement of Asp 105 with Ala was initiated to probe the 
contribution made to binding of the only acidic side-chain group in the 
parent peptide (Table 14). Increasing the chain length by incorporating 
glutamic acid at this position appeared to significantly reduce the 
binding efficiency as did the removal of the carboxy function by 
substituting alanine (a 12 fold increase in IC 50 was observed). This tends 
to implicate this amino acid in the binding interaction. 
2.10 Summary and Conclusions 
The initial aim of this study was to isolate a region on the NGF protein 
sequence capable of demonstrating significant levels of interaction with 
the low affinity gp75.NGFR The competitive assay developed from a 
recombinant form of this receptor was used to probe levels of inhibition 
in binding of 1251-NGF by our test peptides. This system led initially to 
the discovery of 95-120, a peptide chosen from the C-terminal region of 
the protein. Subsequent dissection of this fragment led to the isolation of 
the minimum structural unit which was found to be 100-114: 
100 	 114 
Arg.Phe.Ile.Arg.Ile.Asp.Thr.Ala.Cys.Val.Cys.Val.Leu.Ser.Arg:1C 50 3 p.M 
Removal of either Arg 100 or Arg 114 from this peptide led to 
compounds with no inherent binding affinity for the NGF receptor. This 
study therefore provides direct evidence of the functional importance of 
these side-chains in the recognition process. 
The introduction of amino acid replacements to the parent unit has so 
far failed in reducing the IC 50 value further. Some of the substitutions 
caused only slight decreases in binding efficiency while others resulted 
in the complete inactivation of the peptide in the assay. This tends to 
indicate a high degree of specificity associated with the receptor 
interaction. The modifications may not signify a critical involvement to 
receptor binding of all the side-chains in this sequence but may reflect 
the disruption of secondary structural elements within the peptide which 
are critical in the formation of the bioactive conformation. 
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This hypothesis may also explain the increased binding noted for the 
oxidised form of these peptides. The preference for the 1,3 disulphide 
may reflect the stabilisation of structural elements, possibly a y-türn, in 
these sequences. Such a turn may influence the spatial orientation of the 
amino acids contained in the sequence which directly make contact with 
the receptor. Structural analysis of gp75NGFR  shows that it is a highly 
acidic protein containing four cysteine rich repeat sequences. 76 It seems 
likely therefore that the residues Arg 100, Arg 103 and Arg 114 form a 
positively charged unit which interacts with an oppositely charged 
region on the receptor. 
Although this peptide shows significant levels of inhibition a 
comparison with the intact NGF protein shows that binding is around 
1000 times weaker. If the recognition process is controlled mainly by 
electrostatic charge interactions then a consideration of the other basic 
residues in the sequence may be important in reducing the IC 50 value 
further. The apparent lack of increased binding from the C-terminal third 
of NGF contained in peptide 81-120 may rule out a major contribution of 
Lys 95. Analysis of the computer graphics representation of 100-114 
shows the close proximity of Lys 32 and Lys 34 to Arg 100. The peptide 
25-54 containing both these lysine residues has been tested in the assay 
and shows a 20% inhibition in 12 I-NGF binding at 100 pM. When this 
is compared to the peptide 100-114 (>95% @ 100) it seems 
insignificant, but compared to the 0% inhibition levels found for other 
peptides synthesised from this region, this result may be worthy of 
further investigation. Further evidence for this comes in a recent 
publication from Ibanez et al. 145 who, using site directed mutagenisis, 
showed that considerable reductions in the levels of binding to gp75NGFR 
were found in mutants containing the replacements Lys 32 Ala and Lys 
34 Ala. Computer analysis clearly shows that both these lysine residues 
and the three arginine residues Arg 100, Arg 103, and Arg 114 are 
arranged along the length of one side the protein structure. This may 
suggest that a large active site pocket exists for the docking of NGF with 
this receptor. Future synthetic studies on analogues of the peptide 100-
114 may include N-terminal extensions containing lysine residues in a 
bid to improve the IC50 value. 
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The results presented in this dissertation implicate for the first time a 
highly conserved region from the C-terminus of NGF which is involved 
in the receptor recognition process. It is hoped that this information may 
provide a starting point for the construction of compounds with agonist 
or antagonistic properties specific for neurotrophin receptors. Such 
compounds may be of pharmacological interest in the treatment of 
neurological disease. 
2.11 The Synthesis of hNGF (54) 
The recent advances in solid phase peptide synthesis have now made it 
possible to synthesise, purify and characterise large polypeptides and 
small proteins. Recent efforts in this laboratory have shown that it is 
possible to assemble, cleave and purify the 76 residue protein ubiquitin 
in quantities of up to 100 Mg. 171 The high purity of the synthetic material 
allowed for the extensive structural determination using both X-ray 
crystallography and high field NMR. These studies revealed a close 
similarity of the folded synthetic material to an authentic sample of 
ubiquitin. 
The synthetic protocols, now well established for the synthesis of 
ubiquitin analogues, were employed in the assembly of human NGF. 
The scale of the synthetic problem however, far exceeds in complexity 
that of ubiquitin and special considerations have to be made. The 
incorporation of 3 disulphide bridges into synthetic NGF represents a 
significant challenge to the peptide chemist. The formation of the correct 
disulphide bridges, which serve to stabilise important structural 
elements, may be critical in the generation of biologically active protein. 
The overall synthetic strategy therefore used S-t-butyl protection for Cys 
108 and 58, and Acm protection for Cys 110, 68, 80 and 15. This 
allowed for the possibility of selective disulphide formation. 
The first attempt to synthesise hNGF employed rapid HOBt ester 
couplings (3/4 hour). This exploratory synthesis was initiated to identify 
areas in the protein assembly where amino acid incorporation was 
significantly reduced. The deprotection profile was once again used as a 
guide. The first 20 amino acids were also assembled manually on the 
bubbler apparatus (Appendix I). This obviates the coupling problems 
which are often encountered during the assembly of the first 15 residues 
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due to the incompatible nature of the growing peptide chain, resin matrix 
and the solvents. Each coupling step during the manual synthesis could 
also be monitored by the ninhydrin test for primary amines. 172 Cleavage 
of an aliquot of resin after 20 residues gave a single product of high 
purity on analytical hplc. The remaining resin was transferred to the ABI 
430A peptide synthesiser and the assembly completed using single 
couple cycles. The major area of concern was found to be the residues 
between Phe 53 and Leu 38 which demonstrated a significant drop in 
coupling efficiency. FIG 2.21.a. (solid line) shows a representation of the 
deprotection profile observed for this synthesis. The overall drop was 
calculated to be 75% of the starting value. 
A second synthesis then followed using triple couple cycles (FIG 
2.21.b, broken line) with careful monitoring of the couplings spanning 
the region detailed above. Analysis of the deprotection profile showed a 
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Fig. 2.21. The deprotection profile for the synthesis of hNGF. 
The optimised conditions for the cleavage of resin bound protein and 
deprotection of the acid labile side-chain protecting groups was 
established with cysteine protection remaining intact. The crude material 
was found to be readily soluble in acetic acid solutions and this allowed 
initial purification of the crude product on a Sephadex G50 gel filtration 
column. This form of chromatography works on the principal of size-
exclusion, the products of smallest molecular weight being retained on 
the column while the larger components pass freely through the system. 
This technique was found to be successful in the removal of large 
quantities of deletion sequences from the crude protein solution. A 
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comparison by amino acid analysis of the crude material with the gel 
filtered product showed significant improvement in the latter (Table 19). 
All attempts to further purify this material by ion-exáhange 
chromatography were unsuccessful. Analysis of the gel filtered material 
using SDS gel electrophoresis run against a series of protein molecular 
weight standards showed that although a band was present at the correct 
position, a considerable number of truncated sequences still 
contaminated the product The very small differences in molecular 
weight observed between these deletion sequences hampered further 
purification at this stage. 
The purification protocols of mNGF by ion exchange chromatography 
are well documented in the literature. 173 It was therefore decided to fully 
deprotect the cysteine residues of the partially purified material and 
attempt the regeneration of the disulphides using a modified version of a 
method first published by Saxena.174a Early experiments showed that it 
was possible to significantly improve the purity of crude NGF protein 
solutions using a 10,000 MW cut off dialysis bag. The fully deprotected 
protein (20 mg) was firstly denatured in 7M guanidinium hydrochloride, 
0.1M tris buffer, pH 8 (200 ml), containing 0.01% mercaptoethanol. 
Sequential dialysis (10,000 MWCO) against several changes of 4M and 
2M guanidinium hydrochloride solutions was carried out as above. 
Oxidation and regeneration of the hNGF was then performed in 2M 
guanidinium hydrochloride, 0.1M tris, pH 8, in 0.3 mM oxidised and 
0.15 mM reduced glutathione for 18 hours.174b The solution was then 
dialysed against 0.1M tris buffer pH 8, distilled water and 1M acetic 
acid. Lyophilisation of the clear solution yielded 5 mg of product. The 
analytical hplc trace of this material is shown in FIG 2.22. 
Biological testing of the synthetic material showed no inhibition of 
1251..NGF binding in the receptor assay. The manual assembly of the first 
20 residues (101-120) of synthetic IINGF showed, after cleavage, that 
this region of the protein was incorporated in high yield and should 
therefore be present in all the deletion sequences. As this peptide inhibits 
1251...NGF binding in its own right, then it would appear that the critical 
amino acids in this region (Arg 100, 103 and 114) are prevented from 
adopting a recognisable bioactive conformation. The general conclusion 
can therefore be made that the protein was incorrectly folded and as a 
consequence biologically inactive. 
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FIG 2.22. HpIc trace of oxidised synthetic NGF. 
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Chapter 3 Experimental 
3.1 Notes 
All Fmoc-amino acids were purchased from either Novabiochem or 
Raylo, and unless otherwise stated were of the L-configuration. The 
peptides described were synthesised either on an ABI 430A automated 
peptide synthesiser or using the manual bubbler apparatus described in 
Appendix I. The peptide synthesiser was fitted with a monitoring system 
consisting of either an Applied Biosystems 757 absorbance detector and 
a Hewlett Packard HP339A integrator or an Applied Biosystems 759A 
absorbance detector and a Spectra Physics Chrom Jet integrator. Peptide 
synthesis grade dimethylformamide (DMF) and 1 ,4-dioxan were 
obtained from Rathbum Chemicals. Peptide synthesis grade 
trifluoroaceteic acid (TFA) was supplied by Applied Biosystems. Amino 
acid analysis was carried out on an LKB 4151 amino acid analyser 
following sealed Carius tube hydrolysis with constant boiling 
hydrochloric acid at 110°C for 16-48 hours depending on peptide length. 
High performance liquid chromatography (hplc) was carried out using 
either a Waters system consisting of 2 X 600A pumps, a U6K injector, a 
680 automatic gradient controller and a model 441 ultraviolet detector or 
an Applied Biosystems machine consisting of 2 X 1406A solvent 
delivery systems, a 1480A injector/ mixer and a 1783A detector/ 
programmer. Ultraviolet spectra were recorded on a Varian Cary 210 
spectrophotometer. A Kratos MS50TC machine was used for the 
measurement of both high and low resolution fast atom bombardment 
(FAB) spectra. Proton nuclear magnetic resonance (NMR) spectra of 
peptide solutions were recorded on a Varian VXR 5000 (600 MHz) 
machine in 9:1 H20/ D20 or in d6-DMSO. Peptide sequencing was 
performed by Welmet on an Applied Biosystems 477A protein 
sequencer. Protein molecular weight determination and isoelectric 
focussing were performed using Pharmacia ExcelGel precast gels. 
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3.2 Solid Phase Peptide Synthesis 
3.2.1 Coupling the First Amino Acid to the p-Alkoxybenzyl Alcohol 
(Wang) Resin. Symmetrical Anhydride Formation 
To a solution of the Fmoc-amino acid (4.7 mmol) in 
dimethylformamide (DMF, 20 ml) was added N,N'-
diisopropylcarbodiimide (DIC, 0.36 ml, 2.4 mmol). The mixture was 
stirred for 15 minutes and added to p-alkoxybenzyl alcohol resin (0.79 
mmolg-1 , 1.0 g, crosslinked with 2% divinylbenzene) pre-swollen in 
DMF (5m1). To this was added 4-(N,N-dimethyl)aminopyridine (DMAP, 
10 mg, Aldrich Chemicals), in DMF (2ml) and the mixture sonicated for 
2 hours. The resin was filtered off and washed well with several portions 
of DMF before being transferred to a clean reaction vessel. 
3.2.2 Coupling the First Amino Acid to the 2-Copolv(styrene-1%-
divinylbenzene)methoxv-5-(9'-fluorenylmethoxycarbonylamino)dibeflzO-
cycloheptadiene (Amide) Resin. Svmmetncal Anhydride Formation 
All peptide amides were assembled on an ABI 430A peptide 
synthesiser. Amide resin (0.5 mmol, 0.54 mmolg-1 , 0.92 g) was firstly 
Fmoc deprotected with a solution of 20% piperidine/ DMF for 5, 3, 3 
and 1 minute periods. The resin was then washed with 50% DMF/ 
dioxan (5 X 8 ml) and drained. Peptide assembly was carried out using 
standard double couple cycles (section 3.2.6) unless otherwise stated. 
3.2.3 Determination of Resin Loading 
The loading of the Fmoc-amino acid derivatised resin was determined as 
follows. An aliquot of Fmoc-amino acid resin (from section 3.2.1) was 
washed with dichioromethane (DCM, 5 X 10 ml) and diethyl ether (5 X 
20 ml) and dried in vacuo overnight. To an accurately weighed sample 
of dried resin (2-4 mg) in a 10 ml volumetric flask was added a 20% 
solution of piperidine in DMF. After sonication for 15 minutes the UV 
absorbance of the supernatant was measured at 302 rim. The loading was 
calculated by computer programme utilising the Beer-Lambert law after 
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calibration with known quantities of Fmoc-Gly-OH. The values for 
individual resin samples are listed in the text. 
3.2.4 Resin Capping 
In most cases a less than quantitative incorporation of first amino acid 
onto the resin was found to be optimal. This meant that the resin still 
contained functional hydroxyl groups. These sites were capped using the 
following procedure. 
Resin pre-swollen in DMF (20 ml) was cooled to 0°C in a salt/ ice 
bath. Benzoyl chloride (0.5 ml) and Pyridine (0.5 ml) were added and 
the mixture sonicated for 15 minutes. The resin was then filtered and 
excess reagents removed by washing with DMF before transfer to the 
bubbler or the ABI 430A peptide synthesiser. 
3.2.5 Manual Method for Peptide Synthesis 
The synthesis schedule for deprotection and coupling during manual 
peptide synthesis is shown in Table 16. 
DMF wash (10 x 1 minute) 
20% Piperidine/ DMF 1 x 3 minutes 
20% Piperidine/ DMF 1 x 7 minutes 
DMF wash (10 x 1 minute) 
Ninhydrin test 
Fmoc-amino acid coupling (1 x 1 hour) 
DMF wash (10 x 1 minute) 
Ninhydrin test 
L If -ye return to step b. and continue. 
If +ve return to step f. 
Table 16 
All Fmoc-amino acids were coupled manually as their symmetrical 
anhydrides on a 0.5 mmol scale unless otherwise stated. 
To a solution of Fmoc-amino acid (3 mmol) in DMF (15 ml) was 
added DIC (0.23 ml, 1.5 mmol). The mixture was stirred for 15 minutes 
before addition to the Nadeprotected resin (0.5 mmol) in the bubbler 
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{Fmoc-Gln-OH and Fmoc-Asn-OH were coupled as the 1-
hydroxybenzotriazole (HOBt) ester. The Fmoc-amino acid (1.5 mmol) 
was dissolved in DMF (15 ml) then DIC (0.23 ml, 1.5 mmol) and HOBt 
(0.2 g, 1.5 mmol) added. The mixture was stirred for 20 minutes before 
addition to the bubbler]. 
At the end of each coupling cycle or after a deprotection, a sample of 
peptide-resin was removed from the bubbler and placed in a small glass 
test tube. To this sample was added 3-drops each of the three ninhydrin 
reagents detailed below. The tubes were placed in a heating block at 
1000C. After 5 minutes the colour of the resin beads and the ninhydrin 
solution were observed. Free amino groups reacted giving a dark blue 
colour while negative tests, indicating complete amino acid 
incorporation, gave pale yellow solutions and clear beads. 
Solution 1: Reagent grade phenol (40 g) was dissolved in 10 ml of absolute ethanol. 
Solution 2: KCN (65 mg) was dissolved in 100 ml of distilled water. 2m1 of this 
solution was diluted to 100 ml with pyridine (freshly distilled from ninhydrin). 
Solution 3: Ninhydrin (2.5 g) was dissolved in 50 ml of absolute ethanol. 
3.2.6 Automated Peptide Synthesis 
Automatic assembly on the ABI 430A peptide synthesiser was carried 
out on either a 0.5 mmol or 0.25 mmol scale. Fmoc-amino acids (1.0 
mmol for 0.5 mmol scale and 0.5 mmol for 0.25 mmol scale), pre-
weighed in cartridges, were loaded into the machine. The amino acids 
were activated as either the symmetrical anhydride or the HOBt ester. 
The procedure for a 0.5 mmol scale synthesis is described below. 
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3.2.6.1 Symmetrical Anhydride Activation 
Fmoc-amino acid (2.0 mmol) was dissolved in DMF (8 ml) and a 
solution of 0.5M DIC in 1,4 dioxan (2.0 ml, 1.0 mmol) added. The 
solution was allowed to stand for 10 minutes before transfer to the 
reaction vessel. 
3.2.6.2 1-Hvroxvbenzotriazole (HOBO Ester Activation 
Fmoc-amino acid (1 mmol) was dissolved in DMF (8 ml) and treated 
with a solution of 0.5M DIC in 1,4 dioxan (2.0 ml, 1 mmol) and 0.5M 1-
hydroxybenzotriazole in DMF (2.0 ml, 1.0 mmol). The solution was 
allowed to stand for 20 minutes before transfer to the reaction vessel. 
3.2.6.3 Coupling Cycles 
The activated amino acids were allowed to couple with the N-
deprotected resin for a period of time specified by the synthesis 
programme. The most commonly used cycle was the standard double 
couple cycle which firstly employed a symmetrical anhydride coupling 
followed immediately by an HOBt ester coupling. All the coupling 
cycles used in automated peptide synthesis are listed in Table 17 and 
will be referred to in the text. 
Cycle Name Coupling Time Activation 
Single Couple Cycle 1/2 hour HOBt Ester 
Standard Double Couple 1/2 hour Symmetrical Anhydride 
Cycle 1/2 hour HOBt Ester 
Extended Double Couple 1 hour Symmetrical Anhydride 
Cycle 1 1t2 hour HOBt Ester 
Standard Triple Couple 1/2 hour Symmetrical Anhydride 
Cycle 1/2 hour HOBt Ester 
1/2 hour HOBt Ester 
Extended Triple Couple 1 hour Symmetrical Anhydride 
Cycle 1 1t2 hour HOBt Ester 
1 1f2 hour HOBt Ester 
Double Couple Cycles 1/2 hour HOBt Ester 




At the end of each coupling step excess reagents were removed by a 
series of 50% DMF/ dioxan washes (6 X 8 ml). 
3.2.6.4 Resin Capping 
The resin was capped after each coupling step by the addition of 1 ml 
of 0.5M acetic anhydride in DMF and 1 ml of 0.5M pyridine in DMF. 
The solution was diluted to 6 ml with 50% DMF/ dioxan. Capping was 
allowed to proceed for 2.5 minutes before drainage. The resin was 
washed with DMF/ dioxan (2 X 8 ml) and a second capping cycle 
initiated for 3.5 minutes. Excess reagents were then removed by a further 
series of 50% DMF/ dioxan washes (5 X 8 ml). 
3.2.6.5 N-Deprotection 
After each coupling step the peptide resin was deprotected sequentially 
with a solution of 20% piperidine in DMF for 5, 3, 3 and 1 minute 
periods. An aliquot of each solution was removed after each deprotection 
and the solution passed through a UV detector connected to an 
integrator. A deprotection profile showing a semi-quantitative measure 
of the previous coupling reaction was thus obtained. After the final 
deprotection step the resin was washed with 50% DMF/ dioxan (5 X 8 
ml) and drained ready for the next amino acid addition. 
3.2.7 Acidolytic Deprotection 
On completion of a synthesis the peptide-resin was transferred to a 
sintered glass funnel and washed with DCM (5 X 20 ml) and diethyl 
ether (5 X 20 ml). The air dried peptide-resin was treated with 95% 
aqueous TFA (20 ml) containing a mixture of scavengers and under 
nitrogen with gentle stirring. The choice of scavenger mixture was 
dependant on amino acid sequence and is shown in Table 18. 
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Amino Acid Scavenger Mixture 
Gly, Ala, Val, He, 
Leu, Phe, Tyr, Asn None 
Gin, Pro, Asp, Glu 
Lys, Ser, Thr, Tyr  
His (Bum) Ethanedithiol 5% 
Met Ethylmethylsuiphide 
5% 
Arg (Pmc) Phenol 2.5% 
Anisole 2.5% 
Trp Anisole 2.5% 
Ethanedithiol 2.5% 
Cys 	S t-Butyl None 
Trityl Ethanedithiol 5% 
Acm None 
Table 18 
Aliquots of the reaction mixture were analysed at regular intervals by 
analytical hplc to determine the optimal cleavage time. At the end of the 
cleavage period the resin was filtered. The filtrate was then dried in 
vacuo to give an oily residue. Addition of diethyl ether (50 ml) gave the 
peptide as a white solid. The solid was filtered off and washed with 
diethyl ether (3 x 50 ml). 
3.2.8 Peptide Analysis and Purification 
3.2.8.1 Analytical Hplc 
Qualitative assessment of all crude peptides was made by analytical 
hplc using either an Aquapore RP 300 C 18 reversed-phase silica column 
(300 A pore size, 7 pm spherical silica, 20 cm X 0.46 cm) or a Vydac 
218TP54, C 18 reversed phase silica column (300 A pore size, 5 pm, 20 
cm X 0.46 cm). Sample injections were made onto a 100 .tl loop unless 
otherwise stated. Columns were eluted with a gradient of acetonitrile (far 
UV grade, Rathburn Chemicals, solvent B) containing TFA (0.1%) and 
water with TFA (0.1%, spectrophotometric grade FSA, solvent A) at a 
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flow rate of 1 ml! minute. The eluent was monitored at 214 nm unless 
otherwise stated. 
3.2.8.2 Preparative Hplc 
Peptides were purified by preparative reversed-phase hplc using one of 
two Aquapore RP 300 semi-prep columns containing the same packing 
as above (long, 20 cm X 1.0 cm and short, 11 cm X 1.0 cm) or on a 
Vydac TP1022 preparative column (20 cm X 2.5 cm). Aliquots of the 
crude material (5-10 mg for Aquapore cartridges and 20-50 mg for 
Vydac column) were dissolved in 10-30% aqueous acetic acid (2-5 ml) 
unless otherwise stated and filtered through a 4 l.tm  filter (Gelman). The 
filtered sample was then injected onto the column and eluted as before 
with a gradient of acetonitrile and water at a flow rate of 5 ml/ minute 
for the Aquapore columns, and 10 ml/ minute for the Vydac preparative 
column. Purified peptides were obtained on lyophilisation following the 




The Synthesis of NGF 21-36 (19) 
H-Trp-Val-Gly-Asp-Lys-Thr-Thr-Ala-Thr-Asp-fle-Lys-Gly-Lys-Glu-
Val-OH 
The peptide was assembled manually as described in section 3.2.5 on 
Fmoc-Val-Resin (1.06 g, 0.47 mmolg -1 , 0.5 mmol). Resin bound peptide 
was cleaved for 1.5 hours in TFA containing 5% H0, 2.5% anisole and 
2.5% ethanedithiol (EDT). 
Purification of the crude peptide (30 mg) by preparative hplc 
(Aquapore RP 300, 11 cm cartridge) using a 5 to 50% B gradient over 30 
minutes yielded 18 mg of the title compound after lyophilisation; amino 
acid analysis: Asx2 1.92, Thr3 2.61, G1x 1 1.22, Gly2 1.94, Ala 1 1.01, 
Va12 1.99, lIe 1 0.97, Lys3 3.01, Trp 1 not detected; m/z (FAB) 1748.3 
(Mt), HRMS C77H127N20026 requires 1747.92297 found 1747.92291; 
hplc (Aquapore RP 300, 10-50% B over 30 minutes), R t = 19 minutes. 
The Synthesis of NGF 41-46 (20) 
H-Glu-Val-Asn-Ile-Asn-Asn 
The peptide was assembled on the ABI 430A peptide synthesiser as 
described in section 3.2.6 using standard double couple cycles and on 
Fmoc-Asn-Resin (1.2 g, 0.41 mmolg- 1 , 0.5 mmol). The resin bound 
peptide was cleaved for 2 hours in 95% aqueous TFA. 
Purification of the crude peptide (50 mg) by preparative hplc 
(Aquapore RP 300, 20 cm cartridge) using a gradient of 5-30% B over 
30 minutes (A = 0.01M ammonium acetate [pH 8],  B = acetonitrile) 
yielded 10 mg of the title compound after lyophilisation; amino acid 
analysis: Asx 3 2.78, Glx 1 1.07, Val 1 0.98, Ile 1 0.96; m/z (FAB) 702 
(M), HRMS C28H47N9012 requires 702.34221 found 702.34224; hplc 
(Aquapore RP 300, 5-50% B over 30 minutes), R t = 17 minutes. 
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The Synthesis of NGF 66-72(21) 
H-Ser-Gly-Cys-Arg-Gly-Ile-Asp-OH 
The peptide was assembled manually as described in section 3.2.5 on 
Fmoc-Asp(OBu')-Resin (0.94 g, 0.53 mmolg- 1 , 0.5 mmol). The cysteine 
residue was incorporated as the trityl derivative. Resin bound peptide 
was cleaved for 2 hours in TFA containing 5% H20, 5% EDT. 
Purification of the crude peptide (40 mg) by preparative hplc 
(Aquapore RP 300, 20 cm cartridge) using a 5-50% B gradient over 30 
minutes yielded 23 mg of the title compound after lyophilisation; amino 
acid analysis: Asx 1 1.11, Serf 0.94, G1y2 2.12, Be 1 0.90, Arg 1 0.99, Cys 1 
not detected; m/z (FAB) 707 (M), HRMS C 26H46N 10011 S 1 requires 
707.31462 found 707.31460; hplc (Aquapore RP 300, 5-50% B over 30 
minutes), Rt  = 14.0 minutes. 	 - 
The Synthesis of NGF 74-91 (22) 
H-Lys-His-Trp-Asn-Ser-Tyr-Cys-Thr-Thr-Thr-His-Thr-Phe-Val-Lys-
Ala-Leu-Thr-OH 
The peptide was assembled manually as described in section 3.2.5 on 
Fmoc-Thr(Bu')-Resin (0.92 g, 0.54 mmolg- 1 , 0.5 mmol). The cysteine 
residue was incorporated as the trityl derivative. Resin bound peptide 
was cleaved for 4 hours in TFA containing 5% H20, 2.5% EDT and 
2.5% anisole. 
Purification of the crude peptide (75 mg) by preparative hplc 
(Aquapore RP 300, 20 cm cartridge) using a 10-30% B gradient over 30 
minutes yielded 13.4 mg of the title compound after lyophilisation; 
amino acid analysis: Asx 1 1.15, Thr5 4.50, Ser1 0.95, Ala 1 1.16, Val1 
1.01, Leu1 0.95, Tyr1 0.98, Phe 1 0.97, His2 2.18, Trp 1 not detected, Lys2 
1.99, Cys 1 not detected; m/z (FAB) 2138.9 (M), HRMS 
C97H1 N027S 1 requires 2139.05259 found 2139.05249; hplc 
(Aquapore RP 300, 10-75% B over 75 minutes), R t = 17.0 minutes; the 




The Synthesis of 1INGF 95-120 (23) 
H-Lys-Gln-Ala-Ala-Trp-Arg-Phe-Ile-Arg-Ile-Asp-Thr-Ala-CYS-Val-CYS-
Val-Leu-Ser-Arg-Lys-Ala-Val Arg-Arg-Ala-OH 
The peptide was assembled manually as described in section 3.2.5 on 
Fmoc-Ala-Resin (0.86 g, 0.58 mmolg-1 , 0.5 mmol). The cysteine 
residues were both incorporated as the trityl derivative. A positive 
ninhydrin test was observed for Arg 100 after a 1 hour coupling cycle. 
This residue was recoupled using the BOP reagent' 75 [To Fmoc-
Arg(Prnc)OH (1.32 g, 2.0 mmol) and HOBt (0.27 g, 2.0 mmol) in DMF 
(20 ml) was added BOP reagent (0.88 g, 2.0 mmol) followed by 
diisopropylethylamine (DIPEA, 1.04 ml, 6 mmol). The mixture was 
stirred for 2 minutes and added to the peptide-resin in the bubbler]. 
Resin bound peptide was cleaved for 3 hours in TFA containing 2.5% 
H20, 2.5% anisole, 2.5% EDT and 2.5% phenol. 
Purification of the crude peptide (60 mg) by preparative hplc 
(Aquapore RP 300, 11 cm cartridge) using a 10-50% B gradient over 30 
minutes yielded 12 mg of partially purified material after lyophilisation. 
Further purification (Aquapore RP 300, 11 cm cartridge) using a 10-40% 
B gradient over 30 minutes yielded 5 mg of the title compound after 
lyophilisation; amino acid analysis: Asx 1 1.10, Thr, 0.94, Ser f 0.93, Gix, 
1.10, Ala5 5.31, Va13 2.95, lie2 1.98, Leu 1 1.04, Phe, 1.00, Trp 1 not 
detected, Lys 2 2.06, Ar95 5.03, Cys2 not detected; m/z (FAB) 3018.0 
(M), HRMS C 132H225N45032S2 requires 3018.69143 found 3018.69131; 
hplc (Aquapore RP 300, 10-70% B over 25 minutes), R = 23.0 minutes. 
The Synthesis of hNGF 50-54 (24) 
H-Lys-Gin-Tyr-Phe-Phe-OH 
The peptide was assembled manually as described in section 3.2.5 on 
Fmoc-Phe-Resin (0.98 g, 0.51 minolg -1 , 0.5 mmol). On completion of 
the synthesis an aliquot of resin (400 mg) was removed and cleaved in 
95% aqueous TFA for 1.5 hours. No further purification of the title 
compound was required; amino acid analysis: G1x 1 1.19, Tyr 1 0.97, Phe2 
2.07, Lys 1 1.00; m/z (FAB) 732 (M), HRMS C 38H49N708 requires 
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732.37206 found 732.37203; hplc (Aquapore RP 300, 10-50% B over 20 
minutes), Rt = 15.0 minutes. 
The Synthesis of hNGF 46-54 (25) 
H-Asn-Ser-Val-Phe-Lys-Gln-Tyr-Phe-Phe-OH 
The peptide was assembled manually as described in section 3.2.5 on 
resin loaded with peptide (from 24). An aliquot of resin bound peptide 
(150 mg) was cleaved for 1.5 hours in 95% aqueous TFA. 
Purification of the crude peptide (20 mg) by preparative hplc 
(Aquapore RP 300, 11 cm cartridge) using a 10-75% B gradient over 30 
minutes yielded 12 mg of the title compound after lyophilisation; amino 
acid analysis: Asx 1 0.81, Ser 1 0.85, G1x 1 1.12, Val 1 1.21, Tyr1 0.96, Phe 3 
2.96, Lys 1 1.01; m/z (FAB) 1179 (M), HRMS C59H78N 12014 requires 
1179.58383 found 1179.58382; hplc (Aquapore RP 300, 10-90% B over 
30 minutes), R t  = 17.0 minutes. 
The Synthesis of hNGF 25-54 (26) 
H-Lys-Thr-Thr-Ala-Thr-Asp-Ile-Lys-Gly-Lys-Glu-Val-Met-Val-LeU-
Gly-Glu-Val-Asn-Ile-Asn-Asn-Ser-Val-Phe-Lys-Gln-Tyr-Phe-Phe-OH 
The peptide resin from the previous synthesis (25) was transferred to a 
reaction vessel and the remaining amino acids coupled on the ABI 430A 
peptide synthesiser using standard double couple cycles. The resin 
bound peptide (150 mg) was cleaved for 12 hours in TFA containing 5% 
H20,5% EDT. 
The crude peptide (80 mg) was dissolved in 30% aqueous acetic acid 
and charged onto a Sephadex G50 (fine) column (95 X 2.5 cm). The 
column was eluted with 30% acetic acid at a flow rate of 30 ml/ hour 
and the eluent monitored at 254 nm and 276 run. The combined fractions 
were found to contain 37 mg of partially purified product after 
lyophilisation. Further purification by preparative hplc (Aquapore RP 
300, 11 cm cartridge) using a gradient of 10-60% B over 20 minutes 
yielded 15 mg of the title compound after lyophilisation; amino acid 
analysis: Asx4 4.31, Thr3 2.52, Ser 1 1.32, Glx3 3.37, Gly2 1.92, Ala 1 
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0.91, Va!4 4.01, Met 1 0.77, He2 1.90, Leu 1 1.19, Tyr 1 1.12, Phe3 3.64, 
Lys4 3.49; m/z (FAB) 3420.7 (M), HRMS C 156H 6N380S1 requires 
3421.79096 found 3421.79077; hplc (Aquapore RP 300, 10-60% B over 
20 minutes), Rt = 17.5 minutes. 
The Synthesis of hNGF 59-67 (27) 
H-Arg-Asp-Pro-Asn-Pro-Val-Asp-Ser-Gly-OH 
The peptide was assembled manually as described in section 3.2.5 on 
Fmoc-Gly-Resin (1.02 g, 0.49 mmolg- 1 , 0.5 mmol). Resin bound peptide 
was cleaved for 2 hours in TFA containing 5% H20, 2.5% anisole, 2.5% 
phenol. 
Purification of the crude peptide (60 mg) by preparative hplc 
(Aquapore RP 300, 11 cm cartridge) using a gradient of 10-60% B over 
25 minutes yielded 9.7 mg of the title compound after lyophilisation; 
amino acid analysis: Asx 3 3.00, Ser 1 0.86, Gly 1 0.98, Va! 1 1.14, Pr02 
1.99, Arg 1 1.02; m/z (FAB) 956 (M), HRMS C 38H61N13016 requires 
956.44371 found 956.44369; hplc (Aquapore RP 300, 10-70% B over 25 
minutes), R t  = 17.0 minutes. 
The Synthesis of hNGF 15-23 (28) 
H-Cys-Asp-Ser-Val-Ser-Val-Trp-Val-Gly-OH 
The peptide was assembled manually as described in section 3.2.5 on 
Fmoc-Gly-Resin (0.41 g, 0.61 mmolg- 1 , 0.25 mmol). The cysteine 
residue was incorporated as the trityl derivative. Resin bound peptide 
was cleaved for 2 hours in TFA containing 5% H 20, 2.5%, anisole, 2.5% 
EDT. 
Purification of the crude peptide (100 mg) by preparative hplc 
(Aquapore RP 300, 11 cm cartridge) using a gradient of 10-50% B over 
20 minutes yielded 7.5 mg of the title compound after lyophilisation. 
The low levels of recovery were due to the insoluble nature of the crude 
material; amino acid analysis: Asx 1 1.06, Ser2 1.99, G1y 1 0.93, Va13 
3.04, Trp 1 not detected, Cys 1 0.66; m/z (FAB) 951 (M), HRMS 
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C41H62N10014S 1 requires 951.42456 found 951.42454; hplc (Aquapore 
RP 300, 10-55% B over 15 minutes), R t  = 12.0 minutes. 
The Synthesis of hNGF 34-42 (29 
H-Lys-Glu-Val-Met-Val-Leu-Gly-Glu-Val-OH 
The peptide was assembled manually as described in section 3.2.5 on 
Fmoc-Val-Resin (1.2 g, 0.59 mmolg -1 , 0.5 mmol). Resin bound peptide 
was cleaved for 1 hour in TFA containing 5% H20, 5% EDT. 
Purification of the crude peptide (30 mg) by preparative hplc 
(Aquapore RP 300, 11 cm cartridge) using a 10-50% B gradient over 25 
minutes yielded 24 mg of the title compound after lyophilisation; amino 
acid analysis: G1x 2 2.18, G1y 1 1.01, Va13 2.85, Met1 0.95, Leu 1 0.89, 
Lys 1 1.07; m/z (FAB) 1003 (M), HRMS CH 78N10014S 1 requires 
1003.54975 found 1003.54974; hplc (Aquapore RP 300, 5-85% B over 
20 minutes), R = 13.0 minutes. 
The Synthesis of hNGF 14-28 (30)(31) 
R-Val-Cys-Asp-Ser-Val-Ser-Val-Tr-Val-Gly-Asp-Lys-Thr-Thr-Ala-
NH2 where R = H (30) or Acetyl (31). 
The peptide was assembled on the ABI 430A peptide synthesiser as 
described in section 3.2.6 using standard double couple cycles. The 
cysteine residue was incorporated as the trityl derivative. On completion 
of the synthesis half of the Nadeprotected peptide-resin was removed 
from the reaction vessel and a capping cycle carried out (section 
3.2.6.4). Both resin bound peptides were cleaved for 2 hours in TFA 
containing 5% H20, 2.5% anisole and 2.5% EDT. 
Purification of the free amino terminal peptide (30)(50 mg) by 
preparative hplc (Aquapore RP 300, 11 cm cartridge) using a 10-50% B 
gradient over 25 minutes yielded 12 mg of the title compound after 
lyophilisation; amino acid analysis: Asx2 1.99, Thr2 2.06, Ser2 1.80, G1y 1 
1.07, Ala 1 1.03, Va14 3.84, Lys 1 1.01, Tip 1 not detected, Cys 1 not 
detected; m/z (FAB) 1566.6 (M), HRMS C 67H 108N18023 S 1 requires 
91 
Experimental 
1565.76331 found 1565.76334; hplc (Aquapore RP 300, 10-40% B over 
25 minutes), R t  = 14.5 minutes. 
Purification of the crude N-acetyl peptide (31 )(40 mg) using identical 
conditions yielded 13 mg of the title compound (31) after lyophilisation; 
amino acid analysis: Asx2 2.06, Thr2 2.05, Ser2 1.81, G1y 1 1.02, Ala 1 
1.02,. Va14 3.88, Trp 1 not detected, Lys 1 1.03, Cys 1 not detected; m/z 
(FAB) 1608 (Mt), HRMS C69H110N180S1 requires 1607.77387 found 
1607.77388; hplc (Aquapore RP 300, 10-50% B over 20 minutes), R t  = 
13.0 minutes. 
The Synthesis of Ser 15 hNGF 14-28 (32.33 
R-Val-Ser-Asp-Ser-Val-Ser-Val-Trp-Val-G!y-Asp-Lys-Thr-Thr-Ala-
NH2 
where R = H (32) or Acetyl (33). 
The peptide was assembled on the ABI 430A peptide synthesiser as 
described in section 3.2.6 using standard double couple cycles. On 
completion of the synthesis half of the Nadeprotected peptide-resin was 
removed from the reaction vessel. The remainder was subjected to a 
capping cycle (section 3.2.6.4). Both resin bound peptides were cleaved 
for 3 hours in TFA containing 5% H2O, 2.5% anisole and 2.5% EDT. 
Purification of the free amino terminal peptide (32)(50 mg) by 
preparative hplc (Aquapore RP 300, C 8 , 20 cm cartridge) using a 10- 
30% B gradient over 30 minutes yielded 13 mg of the title compound 
after lyophilisation; amino acid analysis: Asx 2 2.04,Thr2 2.09, Ser3 2.62, 
Gly 1 1.05, Ala 1 1.06, Va!4 4.01, Trp 1 not detected, Lys 1 0.96; m/z (FAB) 
1549.8 (Mt), HRMS C67H108N18024 requires 1549.78615 found 
1549.78612; hplc (Aquapore RP 300, 10-50% B gradient over 20 
minutes), Rt = 12.0 minutes. 
Purification of the N-acetyl peptide (33)(40 mg) by preparative hplc 
(Aquapore RP 300, C 8, 20 cm cartridge) using a 10-50% B gradient over 
30 minutes yielded 15 mg of the title compound after lyophilisation; 
amino acid analysis: Asx2 1.99, Thr2 1.97, Ser3 2.66, G1y 1 1.17, Ala 1 
1.08, Va14 3.83, Trp 1 not detected, Lys 1 0.93; m/z (FAB) 1591.7 (M), 
HRMS C69H 111N 18025 requires 1591.79671 found 1591.79665; hplc 
(Aquapore RP 300, 10-40% B over 15 minutes), R t = 11.0 minutes. 
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The peptide was assembled on the ABI 430A peptide synthesiser as 
described in section 3.2.6 using standard triple couple cycles and Fmoc-
Ala-Resin (1.1 g, 0.27 mmolg -1 , 0.3 mmol). The synthesis proceeded 
smoothly as was evinced by the deprotection profile (section 2.4.1). The 
cysteine residues were incorporated as their trityl derivatives. The resin 
bound peptide was cleaved for 4 hours in TFA containing 5% H20, 2.5% 
anisole, 2.5% EDT, 2.5 % EMS, 2.5 % phenol. 
Partial purification of the crude dithiol peptide (200 mg) by preparative 
hplc (Vydac TP1022, 20 cm cartridge) yielded 35 mg of product. 
Observation of the solutions containing this material by analytical hplc 
showed that the peptide soon became contaminated with a major 
impurity (Aquapore RP 300, 10-65% B over 20 minutes, R  [dithiol] = 
19 min, R1 [impurity] = 16 mm). This was reasoned to be an oxidation 
product. The oxidation was studied at Ca. 0.5 mM solution in distilled 
water. The solution was analysed at regular time intervals (t = 0, 90, 180, 
360 minutes followed by 27 hours) and the reaction found to be 
complete after 30 hours. 
A large scale oxidation followed by purification of the disulphide 
bridged product by preparative hplc (Aquapore RP 300, 11 cm cartridge) 
using a 20-50% B gradient over 20 minutes yielded 15 mg of the title 
compound after lyophilisation; amino acid analysis: Asx2 2.27, Thr6 
4.74, Ser 1 0.87, G1x 1 1.12, G1y 1 1.00, Ala6 6.40, Va!4 4.20, Met 1 1.00, 
lie2 2.23, Leu2 2.19, Phe2 2.09, His 1 0.86, Trp 1 not detected, Lys 3 3.08, 
Ar95 5.30, Cys2 not detected; m/z (FAB) (Mt), C 198H328N62053S3 
requires 4521.42 found 4522.8; hplc (Aquapore RP 300, 10-65% B over 
20 minutes), R = 16.0 minutes. 
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The Synthesis of hNGF 95-105 (35) 
H-Lys-Gln-Ala-Ala-Trp-Arg-Phe-Ile-Arg-Ile-Asp-OH 
The peptide was assembled on the ABI 430A peptide synthesiser as 
described in section 3.2.6 using standard double couple cycles and on 
Fmoc-Asp(OBut)-Resin (1.14 g, 0.57 mmolg-1 , 0.5 mmol). The resin 
bound peptide was cleaved for 3 hours in TFA containing 5% H20, 2.5% 
anisole, 2.5% phenol. 
Purification of the crude peptide (50 mg) by preparative hplc (Vydac 
TP1022, 20 cm cartridge) using a 10-50% B gradient over 90 minutes 
yielded 22 mg of the title compound after lyophilisation; amino acid 
analysis: Asx 1 1.04, G1x 1 1.23, Ala2 2.18, Tie2 1.73, Phe 1 1.00, Lys 1 
1.05, Ar92 2.01, Trp 1 not detected; m/z (FAB) 1404 (Mt), HRMS 
C65H 102N20015 requires 1403.79112 found 1403.79106; hplc (Aquapore 
RP 300, 10-50% B gradient over 20 minutes), Rt = 14.0 minutes. 
The Synthesis of hNGF 103-116 (36) 
H-Arg-Ile-Asp-Thr-Ala-Cys-Val-Cys-Val-Leu-Ser-Arg-Lys-Ala-OH 
The peptide was synthesised manually as described in section 3.2.5 on 
Fmoc-Ala-Resin (1.5 g, 0.49 mmolg-1 , 0.75 mmol). The cysteine 
residues were incorporated as the trityl derivative. On completion of the 
assembly an aliquot of peptide-resin (500 mg) was removed and cleaved 
for 3 hours in TFA containing 5% H20, 2.5% EDT, 2.5% anisole and 
2.5% phenol. 
Purification of the crude peptide (140 mg) by preparative hplc (Vydac 
TP1002, 20 cm cartridge) using a 10-40% B gradient over 60 minutes 
yielded 35 mg of the dithiol peptide after lyophilisation. Air oxidation of 
this peptide in distilled water proceeded slowly over 76 hours and did 
not go to completion. The oxidation was carried out by the slow addition 
of a solution of potassium ferricyanide [40 mg K 3Fe(CN)6 in 20 ml H2O] 
dropwise to the peptide solution (0.5 mmol) until a pale yellow colour 
was maintained for one hour. Hplc analysis of the reaction mixture 
showed that disulphide formation was complete after 2.5 hours. The 
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mixture was then concentrated in vacuo to Ca. 5 ml and passed down a 
Sephadex G10 column (20 cm X 1 cm) using 10% aqueous acetic acid as 
eluent. The peptide fractions were combined and once again 
concentrated to Ca. 5 ml. Purification of the peptide solution by 
preparative hplc (Aquapore RP 300, 11 cm cartridge) using a gradient of 
10-50% B over 30 minutes yielded 20 mg of the title compound after 
lyophilisation; amino acid analysis: Asx 1 1.04, Thr 1 0.93, Ser f 0.91, Ala2 
2.35, Va12 2.09, Ile 1 0.98, Leu 1 1.05, Lys 1 1.03, Ar92 1.97, Cys2 not 
detected; m/z (FAB) 1534.2 (M), HRMS C63H113N21019S2 requires 
1532.7996 found 1532.7997; hplc (Aquapore RP 300, 10-70% B over 25 
minutes), Rt  = 16.0 minutes. 
The Synthesis of hNGF 100-116 (38) 
Lys-Ala-OH 
The aliquot of resin removed from the previous synthesis (37) was 
cleaved for 3.5 hours in TFA containing 5% H20, 2.5% anisole, 2.5% 
EDT and 2.5% phenol. 
Partial purification of the crude peptide (100 mg) by preparative hplc 
(Vydac TP1022, 20 cm cartridge) using a 20-50% B gradient over 40 
minutes yielded 19 mg of the dithiol compound after lyophilisation. The 
peptide was dissolved in distilled water (1 mg/ ml) and allowed to air 
oxidise over 48 hours. The oxidised product was further purified by 
preparative hplc (Aquapore RP 300, 20 cm cartridge) using a gradient of 
20-40% B over 30 minutes and yielded 12.5 mg of the title compound 
after lyophilisation; amino acid analysis: Asx 1 1.00, Thr 1 0.87, Ser 1 0.87, 
Ala2 1.82, Va12 1.89, Ile2 1.82, Leu 1 1.02, Phe 1 0.98, Lys 1 0.93, Ar93 
3.01, Cys2 not detected; m/z (FAB) (M), C 84H 145N27022S2 requires 
1951.42 found 1952.7; hplc (Aquapore RP 300, 10-50% B over 20 
minutes), Rt  = 17.0 minutes. 
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8 H [600 MHz, 90% H20/ 10% D201 oxidised 
Chemical Shift (p.p.m.) 
Amino Acid NH aCH PHIS ?H's Others 
Arg 100 - 4.04 1.90, 1.90 CFI2 1.60 6CH2 3.22 
eNH 7.24 
Phe 101 8.84 3.74 3.08, 3.08 
Ile 102 8.18 4.09 1.74 CH2 1.44 8013 0.82 
CH3 1.10 
Arg 103 7.28 4.28 1.74, 1.82 CH2 1.66 8012 3.26 
1.58 cNH 7.28 
Ile 104 8.34 4.18 1.86 CH 2 1.64 8C"3 0.91 
CH3 1.19 
Asp 105 8.69 - 2.86, 2.98 
Thr 106 8.18 4.30 4.20 CH3 1.21 
Ala 107 8.25 4.38 1.40 
Cys 108 7.99 4.72 - 
Val 109 9.45 4.15 - CE!3 1.00 
Cys 110 8.13 4.72 - 
Val 111 8.12 4.15 - CE!3 0.95 
Leu 112 8.37 4.41 1.65, 1.65 a' 1.65 8CH3 0.95 
0.90 
Ser 113 8.24 4.45 3.90 
Arg 114 8.24 4.45 1.90, 1.75 CI-4 1.61 6012 3.22 
eNH 7.22 
Lys 115 8.38 4.30 1.86, 1.78 CE!2 1.46 8CH2 1.72 
cCH 3.05 
eNH 7.56 
Ala 116 	 8.47 4.35 	1.40 
The Synthesis of hNGF N-Acetyl-100-1 16 (39) 
Lys-Ala-OH 
To the Nadeprotected peptide resin (200 mg) from the previous 
synthesis (38) acetic anhydride (1 ml) and pyridine (0.5 ml) was added 
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in DMF (20 ml). The mixture was sonicated for 15 minutes and the resin 
filtered off, washed with DMF (5 X 20 ml), DCM (3 X 20 ml) and 
diethyl ether (3 X 20 ml) then air dried. The resin bound peptide was 
cleaved for 3 hours in TFA containing 5% H20, 2.5% anisole, 2.5% 
EDT and 2.5% phenol. 
Partial purification of the crude peptide (120 mg) by preparative hplc 
(Vydac TP1002, 20 cm cartridge) using a 20-50% B gradient over 50 
minutes yielded 17 mg of the dithiol compound. The oxidation was 
carried out using a solution of K 3Fe(CN)6 as described for compound 
(37) and was found to be complete after 1 hour. During the oxidation 
step an insoluble green precipitate was observed. This was filtered off 
and the solution freeze-dried. Further purification by preparative hplc 
(Vydac TP1002, 20 cm cartridge) using a 20-50% B gradient over 40 
minutes yielded 5 mg of the title compound after lyophilisation; amino 
acid analysis: Asx 1 1.00, Thr, 0.87, Ser 1 0.97, Ala2 1.82, Va12 1.85, 1He2 
1.82, Leu 1 1.02, Phe 1 0.89, Lys 1 0.93, Arg3 3.03, Cys not detected; m/z 
(FAB) (M), C 86H147N27023S2 requires 1991.25 found 1992.5; hplc 
(Aquapore RP 300, 10-70% B over 70 minutes), R = 18.0 minutes. 
The Synthesis of hNGF 97-116 (37) 
HAla-Ala-Trp-Arg-Phe-Ile-Arg-I1e-Asp-Thr-Ala-CyS-Val-CyS-Val-Leu-
Ser-Arg-Lys-Ala-OH 
The synthesis of the title peptide was carried out using the ABI 430A 
peptide synthesiser on the peptide-resin detailed above (36) [after 3 
cycles (Arg 100) an aliquot of resin (500 mg) was removed and cleaved 
(38)]. On completion of the assembly the resin bound peptide was 
cleaved for 3.5 hours in TFA containing 5% H20, 2.5% anisole, 2.5% 
EDT and 2.5% phenol. 
Partial purification of the crude peptide (140 mg) by preparative hplc 
(Vydac TP1022, 20 cm cartridge) using a 20-50% B gradient over 30 
minutes yielded 40 mg of material. The purification was complicated by 
rapid oxidation to the disulphide of the peptide solution. All the 
remaining product was therefore oxidised using K 3Fe(CN)6 as described 
above (36). Final purification by preparative hplc (Vydac TP1022, 20 cm 
cartridge) using a 20-50% B gradient over 50 minutes yielded 17 mg of 
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the title compound after lyophilisation; amino acid analysis: Asx 1 1.05, 
Thr1 0.94, Serf 0.98, Ala4 3.82, Va12 2.05, 11e2 1.75, Leu 1 1.03, Phe 1 
1.10, Lys 1 1.11, Ar93  2.77, Trp 1 not detected, Cys2 not detected; m/z 
(FAB) (M), C 101H 165N31025S2 requires 2279.79 found 2278.7; hplc 
(Aquapore RP 300, 10-65% B over 20 minutes), R t = 9.0 minutes. 
The Synthesis of hNGF 100-113 (40) 
HArgPhe-fle-Arg-Ile-Asp-Thr-Ala-CysVal-Cy5-Val-LeU-Ser-OH 
The peptide was assembled on the ABI 430A peptide synthesiser as 
described in section 3.2.6 using standard double couple cycles on Fmoc-
Ser(But)Resin (1.02 g, 0.49 mmolg -1 , 0.5 mmol). The cysteine residues 
were incorporated as the trityl derivative. The synthesis proceeded well 
up to Ala 107 where 4 deprotection peaks were observed. In previous 
syntheses this has been interpreted to indicate a subsequent slow 
coupling reaction. The deprotection peak for Thr 106 showed a drop of 
Ca. 20% from the previous coupling. The resin bound peptide was 
cleaved for 3 hours in TFA containing 5% H20, 2.5% anisole, 2.5% 
phenol, 2.5% EDT. 
The crude dithiol peptide (100 mg) was dissolved in 5% DMSO I TFA 
and the oxidation allowed to proceed for 1 hour. The TFA was removed 
in vacuo and the product precipitated by the addition of diethyl ether (50 
ml), filtered, then washed well with diethyl ether and air dried. To the 
crude insoluble peptide was added 50% aqueous acetic acid (50 ml). The 
mixture was sonicated for 16 hours and the insoluble material filtered 
off. The filtrate was reduced in volume to Ca. 10 ml and the peptide 
purified by preparative hplc (Vydac TP1002, 20 cm cartridge) using a 
10-60% B gradient over 30 minutes. After lyophilisation 8.3 mg of the 
title compound was obtained; amino acid analysis: Asx 1 1.13, Thr 1 1.00, 
Ser 1 1.30, Ala1 1.20, Va12 2.15, Ile2 1.70, Leu 1 1.10, Phe 1 1.00, Ar92 
1.80, Cys2  not detected; m/z (FAB) 1595.1 (M), HRMS 
C69H116N20019S2  requires 1593.82447 found 1593.82440; hplc 
(Aquapore RP 300, 10-60% B over 15 minutes), R t = 13.0 minutes. 
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The Synthesis of bmBDNF 100-116 (4 1) 
H-Arg-Phe-Ile-Arg-Ile-Asp-Thr-Ser-Cys-Val-Cys-Thr-Leu-Thr-IlerLys-
Arg-OH 
The peptide was assembled on the ABI 430A peptide synthesiser using 
standard triple couple cycles on Fmoc-Arg(Pmc)-Resin (0.5 g, 0.5 
mmolg-1 , 0.25 mmol). The resin bound peptide was cleaved for 12 hours 
in TFA containing 5% H20, 2.5% phenol, 2.5% EDT. 
Partial purification of the crude material (100 mg) by preparative hplc 
(Vydac TP1022, 20 cm column) using a 10-60% B gradient yielded 30 
mg of product. Air oxidation of the dithiol peptide was carried out in 
distilled water (0.2 mg/ ml) for 24 hours. Further purification of the 
lyophilised peptide by preparative hplc (Aquapore RP 300, 11 cm 
cartridge) yielded 5 mg of the title compound; amino acid analysis: isx 1 
1.08, Thr3 2.74, Ser 1 0.95, Va1 1 1.13, lie3 2.84, Leu 1 1.03, Phe 1 0.96, 
Lys 1 1.00, Ar93 2.97, Cys2 not detected; m/z (FAB) (Mt), 
C87H 151N270S2 requires 2023.48 found 2023.2; hplc (Aquapore RP 
300, 10-50 over 20 minutes), R t  = 13.0 minutes. 
The Synthesis of hNGF 100-115 des-Val 109 (4 1) 
H-Arg-Phe-Ile-Arg-Ile-Asp-Thr-Aia-Cys-Cys-Val-Leu-Ser-Arg-Lys-OH 
The peptide was assembled on the ABI 430A peptide synthesiser using 
standard double couple cycles on Fmoc-Lys(Boc)-Resin (1.02 g, 0.51 
mmolg-1 , 0.5 mmol). The cysteine residues were incorporated as the 
trityl derivative. Resin bound peptide was cleaved for 3.5 hours in TFA 
containing 5% H20, 2.5% anisole, 2.5% phenol and 2.5% EDT. 
Purification of the crude peptide (100 mg) by preparative hplc (Vydac 
TP1002, 20 cm column) using a 10-50% B gradient over 40 minutes 
yielded 25 mg of the dithiol peptide. Air oxidation of 15 mg of this 
product in distilled water (30 ml) was followed by analytical hplc and 
found to be complete after 2 weeks. The oxidised product was further 
purified as above yielding 8 mg of the title compound after 
lyophilisation; amino acid analysis: Asx 1 0.90, Thr1 1.01,Ser1 0.77, Ala 1 
1.21, Va1 1 1.00, 11e2 2.10, Leu 1 1.14, Phe 1 1.01, Lys 1 1.05, Ar93 3.14, 
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Cys2 not detected; m/z (FAB) (M), C 76H 1 3 1N25020S2 requires 1779.2 
found 1781.2; hplc (Aquapore RP 300, 10-90% B over 30 minutes), R 1 = 
12.0 minutes. 
H [600 MHz, 90% H20/ 10% D20] Reduced. 
Chemical Shift (p.p.m.) 
Amino Acid 	NH aCH 	13H's 	?H's 	Others 
Arg 100 - 4.04 1.92, 1.92 CH2 1.61 8CH2 3.22 
eNH 7.22 
Phe 101 8.84 4.74 3.07, 3.09 
Ile 102 8.32 4.19 1.88 CH2 1.48 BCH, 0.88 
1.21 
CH3 0.92 
Arg 103 8.30 4.26 1.75, 1.82 CH2 1.66 8CH2 3.26 
1.58 eNH 7.28 
Ile 104 8.16 4.09 1.74 CIT2 1.44 oCR, 0.84 
1.10 
CH3 0.84 
Asp 105 8.66 4.75 2.96, 2.84 
Thr 106 8.29 4.38 4.37 CH, 1.44 
Ala 107 8.18 4.30 1.24 
Cys 108 8.29 4.52 2.59 
Cys 110 8.45 4.58 2.59 
Val 111 8.28 4.14 2.10 CH3 0.98 
Leu 112 8.36 4.42 1.67 CH 1.65 8013 0.96 
0.90 
Ser 113 8.28 4.46 3.88 
Arg 114 8.32 4.40 1.92, 1.78 CH2 1.62 OCH2 3.23 
cNN 7.20 




o H [600 MHz, 90% H20/ 10% D201 Oxidised. 
Chemical Shift (p.p.m.) 
Amino Acid 	NH aCH 	3H's 	yH's 









































































The Synthesis of S -Acetamidomethyl-N-fluorenylmethoxycarbonyl-L-
penicillamine (Fmoc-Pen(Acm)-OH) (46) 
N-11ydroxymethylacetamide (45)(2.14 g, 24.1 mmol) and L-
penicillamine (44)(3.0 g, 20.1 mmol) were dissolved in 10% TFA / H 2O 
(5 ml). The mixture was cooled in an ice-bath and 
trifluoromethanesulphonic acid! TFA (1: 19, 35 ml) added with stirring. 
After 90 minutes stirring under argon, TLC (silica gel 60 F [Merck], n-
butanol/ acetic acid! H 20, 10:2:3) indicated that all the L-penicillamine 
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had reacted. The solvent was removed in vacuo leaving an oil which was 
dissolved in 10% aqueous sodium carbonate (50 ml) and the pH adjusted 
to 10 by the continued addition of further aqueous sodium carbonate. 
The mixture was then cooled in an ice-bath and Fmoc-succinimide (6.7 
g, 20 mmol) dissolved in dioxan (70 ml) added dropwise over 1 hour. 
The reaction was allowed to warm slowly to room temperature then 
stirred for 2 days. The pH of the reaction was monitored and maintained 
at 10 throughout. The mixture was then poured into water (300 ml) 
extracted with ether (3 X 300 ml), acidified with 12M HC1 to pH 2 and 
extracted with ethyl acetate (3 X 100 ml). The combined ethyl acetate 
extracts were washed with 0.1M HC1 (2 X 200 ml), water (2 x 200 ml) 
and brine (2 X 200 ml), dried over magnesium sulphate and after 
filtration, the solvent was evaporated in vacuo. The product (46) was 
recrystallised from hot dichioromethane by the addition of hexane to 
incipient turbidity and allowed to stand at room temperature overnight 
giving a white solid. Yield 5.2 g (59%). 
M.p. 135-1500C, TLC, chloroform! methanol (5:2), Rf= 0.5; []D25  (c= 
0.25, DMF) -24.40; m/z (FAB) 442 (M), HRMS C79H137N24020S2 
requires 443.16405 found 443.16407; k max  (DMF) 260 (c = 19,911), 290 
(9,194), 300 (7522 mol- 1 , dm3 , cm-1 ); Um (DCM), 3580 (s, NH), 3423 
-  	(( I. 	 IT T 	
\ 
	 (' IJ is, NHv), iZ/O S, FWUrl) 	kill, atom. ri S i ., 1 AC I 	a1 1  
St.), 1721 (s, C=O), 1619 (m, arom. CH=CH); 811 (200 MHz, CDC13) 
1.35 (s, 3H, CH3), 1.45 (s, 3H, CH3), 1.95 (s, 3H, CH3), 4.1-4.6 (m, 
6H), 5.85 (d, J= 9.7 Hz, NH), 7.2-7.8 (m, 8H arom.). 
The Synthesis of Pen 108, Pen 110 hNGF 100-114 (43) 
The peptide was assembled to Vãl 111 on the ABI 430A peptide 
synthesiser using standard double couples on Fmoc-Arg(Pmc)-Resin 
(0.52 g, 0.49 mmolg', 0.25 mmol). Residues 110-108 were coupled 
manually with sonication at 500C using symmetrical anhydrides (3 eq.) 
for 2 hours. Fmoc-penicillamine was protected as the acetamidomethyl 
derivative (46). The remaining amino acids were coupled manually in 
the bubbler apparatus as described in section 3.2.5. Resin bound peptide 
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was cleaved for 3 hours in TFA containing 5% H20, 2.5% phenol and 
2.5% anisole. 
Purification of the penicillamine protected peptide (100 fIg) by 
preparative hplc (Vydac TP1002, 20 cm cartridge) using a 10-60% B 
gradient over 30 minutes yielded 30 mg of product. To the protected 
material (20 mg, 11 pmol, 1 eq.) in TFA (5 ml) containing anisole (10 
p1) was added thallium trifluoroacetate (6.7 mg, 13 p.mol, 1.2 eq.) and 
the reaction stirred in an ice-bath for 1 hour. The TFA was removed in 
vacuo and the oxidised product isolated by gel filtration on a Sephadex 
G 25 (eluted with 20% aqueous acetic acid) followed by preparative hplc 
(Aquapore RP 300, 20 cm cartridge) using a gradient of 10-80% B over 
30 minutes. The title compound (5 mg) was obtained after lyophilisation; 
amino acid analysis: Asx 1 1.10, Thr1 0.89, Ser 1 0.86, Ala 1 1.10, Va12 
2.21, Tie2 2.23, Leu 1 2.10, Phe 1 0.96, Ar93 3.06, Pen2 not detected; m/z 
(FAB) 1807.1 (M), HRMS C 79H137N020S2 requires 1805.98817 
found 1805.98830; hplc (Vydac 218TP54, 10-60% B over 20 minutes), 
R = 16.0 minutes. 
The Synthesis of cz-Aminoisobutvric Acid [Aibi hNGF 100-114 (47) 
H-Arg-Phe-Ile-Arg-Ile-Asp-Thr-Aib-Cys-Val-Cys-Val-Leu-Ser-Arg-OH 
The peptide was assembled on the ABI 430A peptide synthesiser using 
extended double couple cycles on Fmoc-Arg(Pmc)-Resin (0.52 g, 0.49 
mmoig- 1 , 0.25 mmo!). Both cysteine residues were incorporated as the S- 
t-butyl sulphenyl derivative. The Aib residue was coupled manually for 
2 hours at 500C with sonication and was activated as a symmetrical 
anhydride (3 eq.). The deprotection profile indicated Ca. 80% 
incorporation of Aib. The remaining residues were coupled using 
extended triple couple cycles. Resin bound peptide was cleaved for 3.5 
hours in TFA containing 5% H20, 2.5% phenol and 2.5% anisole. 
Purification of the cysteine protected peptide (160 mg) by preparative 
hplc (Vydac TP1002, 20 cm column) using a 10-90% B gradient over 30 
minutes yielded 30 mg of material. To 15 mg of this product dissolved in 
95% trifluoroethanol (TFE), tributyiphosphine (50 p1) was added and the 
mixture stirred for 1 hour. The TFE solution was then evaporated in 
vacuo and the product triturated with diethyl ether (3 X 10 ml) and air 
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dried. The dithiol peptide was then dissolved in 5% DMSO/ TFA (10 
ml) and the oxidation monitored by analytical hplc. After Ca. 1 hour the 
TFA was evaporated in vacuo. The residual solution was diluted with 
50% aqueous acetic acid (5 ml) and the oxidised peptide purified further 
by preparative hplc (Aquapore RP 300, 20 cm cartridge) using a gradient 
of 10-80% B over 30 minutes. After lyophilisation, 5 mg of the title 
compound was obtained; amino acid analysis: Asx 1 1.00, Thr1 0.81, Ser1 
1.06, Va12 1.73, Ile2 1.70, Leu 1 0.95, Phe 1 1.03, Ar93 3.01, Cys2 not 
detected, Aib 1 not detected; m/z (FAB) 1765.4 (M), HRMS 
C76H 130N24020S2  requires 1763.94122 found 1763.94119; hplc (Vydac 
218TP54, 10-80% B over 25 minutes), R t  = 14.0 minutes. 
The Synthesis of hNGF 100-114 Analogue (48)(Lactam Bridged N-
terminus to Asp 105 Side-Chain) 
ArgPheIleArgIle-Asp-Thr-Ala-Cys(Acm)-Val-CYS(Acm)-Val-Leu-
Ser-Arg-NH2 
The peptide was assembled on the ABI 430A peptide synthesiser using 
extended double couple cycles on amide resin (0.5 g, 0.54 mmolg', 0.27 
mmol). The cysteine residues were protected as the Acm derivative. 
Resin bound peptide was cleaved for 3 hours in TFA containing 5% 
H20, 2.5% anisole and 2.5% phenol. 
Purification of the crude Acm protected peptide (150 mg) by 
preparative hplc (Vydac TP1022, 20 cm cartridge) using a 10-60% B 
gradient over 30 minutes yielded 22 mg of product. 
To the cysteine protected peptide (15 mg, 8 j.tM, 1 eq.) in DMF (200 
ml) was added diphenyphosphoryl azide (DPPA, 22 mg, 80 pM, 10 eq.) 
and N,N-diisopropylethylamine (DIPEA, 14 p1, 80 p.M, 10 eq.). The 
mixture was stirred at 0°C in a salt/ ice bath for 2 hours then at room 
temperature for 10 days. The solvent was then removed in vacuo leaving 
an oil which was dissolved in 30% aqueous acetic acid (20 ml) and 
extracted with diethyl ether (3 X 20 ml). The peptide solution, which 
consisted of 2 main peaks on analytical hplc, was further purified by 
preparative hplc (Aquapore RP 300, 20 cm cartridge) using a 10-50% B 
gradient over 40 minutes. Lyophilisation yielded 3 mg of the starting 
material and 4 mg of the desired cyclic cysteine protected product; 
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amino acid analysis: Asx 1 1.06, Thr 1 0.70, Serf 1.16, Ala 1 0.97, Va12 
2.02, lie2 1.78, Leu 1 1.11, Phe l 1.00, Ar93 2.99, Cys2 not detected; m/z 
(FAB) 1875.6 (M), HRMS C81H1 N27020S2 requires 1875:02086 
found 1875.02089; hplc (Aquapore RP 300, 10-70% B over 20 minutes), 
R= 13.0 minutes. 
The Synthesis of D-Leu 112 hNGF 100-114 (49) 
H-Arg-Phe-Ile-Arg-Iie-Asp-Thr-Ala-Cys-Val-Cys-Val-D.Leu-Ser-Arg-
OH 
The peptide was synthesised on the ABI 430A peptide synthesiser 
using extended double couple cycles on Fmoc-Arg(Pmc)-Resin (0.51g, 
0.49 mmoig-1 , 0.25 mmol). The cysteine residues were incorporated as 
the S-t-butyl sulphenyi derivative. Resin bound peptide was cleaved for 
3 hours in TFA containing 5% H20, 2.5% anisole, 2.5% phenol. 
Purification of the cysteine protected peptide (160 mg) by preparative 
hplc (Vydac TP1002, 20 cm cartridge) using a 10-90% B gradient 
yielded 40 mg of product. The peptide was deprotected and oxidised as 
described for compound (47). A final purification step was carried out by 
preparative hpic (Aquapore RP 300, 11 cm cartridge) using a 10-90% B 
gradient over 30 minutes and yielded 10 mg of the title compound after 
lyophilisation; amino acid analysis: Asx 1 1.07, Thr 1 1.01, Ser f 1.07, Ala1 
1.00, Va12 1.95, lie2 1.70, Leu 1 1.14, Phe 1 0.89, Ar93 3.02, Cys2 not 
detected; m/z (FAB) 1748.3 (M), HRMS C 75H129N020S2 requires 
1749.92557 found 1749.92565; hplc (Vydac 218TP54, 10-90% B over 
30 minutes), R t  = 20.0 minutes. 
The Synthesis of D-Ile 104 hNGF 100-114 (50) 
H-Arg-Phe-Iie-Arg-D.Ile-Asp-Thr-Ala-Cys-Vai-Cys-Val-Leu-Ser-Arg-
OH 
The peptide was assembled on the ABI 430A peptide synthesiser using 
extended double couple cycles on Fmoc-Arg(Pmc)-Resin (0.51 g, 0.49 
mmoig-1 , 0.25 mmoi). The cysteine residues were incorporated as the S- 
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t-butyl suiphenyl derivative. Resin bound peptide was cleaved for 3 
hours in TFA containing 5% H20, 2.5% anisole and 2.5% phenol. 
Purification of the cysteine protected peptide (100 mg) by preparative 
hplc (Vydac TP1022, 20 cm cartridge) using a gradient of 10-90% B 
over 30 minutes yielded 20 mg of product. The peptide was cysteine 
deprotected and oxidised as described for compound (47). A final 
purification step was carried out by preparative hplc (Aquapore RP 300, 
20 cm cartridge) using a gradient of 10-90% B over 30 minutes and 
yielded 8 mg of the title compound after lyophilisation; amino acid 
analysis: Asx 1 1.12, Thr1 1.01, Serf 1.10, Ala1 1.00, Va12 2.08, lie2 1.90, 
Leu 1 1.20, Phe 1 1.20, Arg3 3.25, Cys2 not detected; m/z (FAB) 1750.1 
(M), HRMS C75H131 N24020S2 requires 1751.94121 found 1751.94115; 
hplc (Vydac 218TP54, 10-90% B over 30 minutes), R t = 14.0 minutes. 
The Synthesis of D-Ile 102 1INGF 100-114(51) 
OH 
The synthesis and cleavage of this peptide was carried out under 
identical conditions to compound (50). 
Purification of the cysteine protected peptide (80 mg) by preparative 
hplc (Vydac TP1022, 20 cm column) using a 10-80% B gradient over 30 
minutes yielded 15 mg of product. The peptide was cysteine deprotected 
and oxidised as described for compound (47) and further purified by 
preparative hplc (Aquapore RP 300, 20 cm column) using a 10-60% B 
gradient over 30 mnutes. Lyophilisation yielded 9 mg of the title peptide; 
amino acid analysis: Asx 1 1.00, Thr1 0.81, Ser 1 0.91, Ala 1 0.80, Va12 
1.60, lie2 1.62, Leu 1 0.99, Phe 1 0.90, Ar93 3.21, Cys2 not detected; m/z 
(FAB) 1751.3 (Mt), HRMS C 75H 129N24020S2 requires 1749.92557 
found 1749.92565; hp!c (Vydac 218TP54, 10-90% B over 30 minutes), 
Rt  = 14.0 minutes. 
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The Synthesis of Ala 105 hNGF 100-116 (52) 
H-Arg-Phe-Ile-Arg-Ile-Ala-Thr-Ala-Cys-Val-Cys-Val-Leu-Ser-Arg-LyS-
Ala-OH 
The peptide was assembled on the ABI 430A peptide synthesiser using 
standard double couple cycles on Fmoc-Ala-Resin (0.9 g, 0.56 mmolg', 
0.5 mmol). The cysteine residues were incorporated as the S-t-butyl 
suiphenyl derivative. Resin bound peptide was cleaved for 3.5 hours in 
TFA containing 5% H20, 2.5% anisole and 2.5% phenol. 
Purification of the crude cysteine protected material (50 mg) by 
preparative hplc (Vydac TP1022, 20 cm cartridge) using a 10-60% B 
gradient over 40 minutes yielded 8 mg of product. The peptide was 
dissolved in 95% aqueous 1FE (10 ml) and tributyiphosphine (20 tl) 
added. After 1 hour the solvent was evaporated in vacuo and the residue 
triturated with diethyl ether (3 x 20 ml) then air dried. Further 
purification of the dithiol peptide was carried out by preparative hplc 
(Aquapore RP 300, 11 cm cartridge) using a 10-60% B gradient over 30 
minutes. The purified product (5 mg) was dissolved in distilled water (50 
ml) and allowed to air oxidise for 16 hours. Lyophilisation yielded 5 mg 
of the title compound; amino acid analysis: Thr 1 1.01, Ser f 0.94, Ala3 
3.07, Va12 2.05, lie2 2.03, Leu 1 1.12, Phe 1 0.84, Lys 1 1.16, Ar93 2.83, 
Cys2 not detected; m/z (FAB) 1906.3 (M), HRMS C 83H 145N27020S2 
requires 1905.06781 found 1905.06802; hplc (Aquapore RP 300, 10-
90% B over 30 minutes), R 1 = 13.0 minutes. 
The Synthesis of Glu 104 hNGF 100-114 (53) 
H-Arg-Phe-Ile-Arg-Ile-Glu-Thr-Ala-Cys-Val-Cys-Val-Leu-Ser-Arg-OH 
The peptide was assembled on the ABI 430A peptide synthesiser using 
extended double couple cycles on Fmoc-Arg(Pmc)-Resin (0.51 g, 0.49 
mmolg- 1 , 0.25 mmol). The cysteine residues were incorporated as the S- 
t-butyl sulphenyl derivative. Resin bound peptide was cleaved for 3.5 
hours in TFA containing 5% H20, 2.5% anisole and 2.5% phenol. 
Purification of the cysteine protected peptide (100 mg) by preparative 
hpic (Vydac TP1022, 20 cm cartridge) yielded 10 mg of product. The 
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peptide was cysteine deprotected and oxidised as described for 
compound (47). A final purification step was carried out by preparative 
hplc (Aquapore RP 300, 20 cm cartridge) using a 10-80% B gradient 
over 30 minutes and yielded 6 mg of the title compound after 
lyophilisation; amino acid analysis: Thr 1 1.05, Ser1 0.93, G1x 1 1.19, Ala 1 
1.03, Va12 2.18, lie2 1.79, Leu 1 1.86, Phe 1 0.98, Ar93 3.13, Cys2 not 
detected; m/z (FAB) 1762.9 (M), FIRMS C76H132N25019S2 requires 
1762.95721 found 1762.95722; hplc (Aquapore RP 300, 10-80% B over 
30 minutes), R = 14.5 minutes. 
The Synthesis of hNGF (54) 
The first 20 couplings were carried out manually on the bubbler 
apparatus on Fmoc-Ala-Resin (1.0 g, 0.08 mmolg', 0.08 mmol) as 
described in section 3.2.5. The Fmoc protected peptide resin was stored 
at 0°C in dioxan. An aliquot of peptide resin (10 mg) was NC 
deprotected and cleaved for 3.5 hours in TFA containing 5% H20, 2.5% 
anisole and 2.5% phenol. Hplc analysis (Aquapore RP 300, 20 cm 
cartridge) using a 10-90% B gradient over 30 minutes showed a single 
product with a retention time of 18 minutes. 
An aliquot of peptide-resin (300 mg) was transferred to the ABI 430A 
peptide synthesiser and the protein assembled using single couple 
cycles. Analysis of the deprotection profile showed that a significant 
drop in coupling efficiency had occurred over the residues Phe 53 to Leu 
38. No further drops were observed. The final loading of Fmoc had 
fallen to around 25% of the starting value. 
A second portion of peptide-resin (300 mg) was then transferred to the 
synthesiser and standard triple couple cycles carried out. During the 
course of this synthesis no dramatic drops were observed from the 
deprotection profile, rather a steady decline was noticed across the 
length of the sequence. The final deprotection peaks were around 50% of 
the starting value. The protein-resin (100 mg) was cleaved firstly for 3 
hours in TFA containing 5% H20, 2.5% EDT, 2.5% anisole, 2.5% EMS 
and 2.5% phenol under nitrogen. After evaporation of the TFA in vacuo 
the crude protein was precipitated and triturated with diethyl ether (3 X 
30 ml). The crude material was then dissolved in TFA containing 
scavengers (as above) and the solution sonicated under nitrogen for a 
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further 3 hours. Evaporation and trituration yielded 55 mg of protein 
after air drying. The crude material was dissolved in 30% aqueous acetic 
acid and charged onto a Sephadex G50 (super fine) gel filtration ôolumn 
(90 cm X 2.5). The column was eluted with 30% aqueous acetic acid (25 
ml/ hour) with monitoring at 254 nm and 277 nm. The protein fractions 
9-12 (67-100 ml) were combined and lyophilised to yield 30 mg of 
partially purified material. A comparison of the amino acid analysis 
results of the crude with the gel filtered product is shown in Table 19. 
To the protein (25 mg, 1.8 pM, 1 eq.) in 95% aqueous 1'FF (20 ml) 
was added tnbutylphosphine (50 p1). The reaction was stirred for 3 hours 
then the TFE removed by evaporation in vacuo. The protein residue was 
triturated with diethyl ether and air dried. The product was then 
dissolved in TFA (15 ml) containing anisole (50 p1) and silver 
trifluoromethanesuiphonate (14 mg, 54 pM, 30 eq.) added. The mixture 
was stirred for 1.5 hours at 0C in a salt/ ice bath. The TFA was then 
removed in vacuo leaving the silver salt. The salt was triturated with 
diethyl ether (3 X 10 ml), air dried, then dissolved in 50% aqueous acetic 
acid (30 ml) and dithiothreitol (100 mg) added. The solution was left 
stirring overnight and the yellow precipitate filtered off. The filtrate was 
then lyophilised leaving a white solid. 
The fully cysteine deprotected product was dissolved in guanidinium 
hydrochloride (GMC1, 7M), tris buffer (0.1M, pH 8), containing 0.01% 
mercaptoethanol (200 ml). The solution was placed in a dialysis bag 
(Spectra por 10,000 MWCO) and sequentially dialysed against 7M (2 x 
11, 16 hours), 4M (3 x 11, 12 hours), 2M (3 X 11, 12 hours) GMC1 
solutions as above. Oxidation and regeneration of the synthetic hNGF 
was then carried out by dialysing against 2M GMC1, tns buffer (0.1M, 
pH 8), in 0.3 mM oxidised and 0.15 mM reduced glutathione (3 X 
500ml, 6 hours). Further dialysis against 0.1 M tris buffer, pH 8, distilled 
water and 1M acetic acid followed by lyophilisation yielded 5 mg of 
product. 
Experimental 
AMINO ACID CRUDE GEL FILT. EXPECTED 
ASX 13.1 13.7 13 
THR 10.1 9.8 10 
SER 7.6 7.7 11 
GLX 6.5 6.0 6.0 
PRO 2.5 2.1 2.0 
GLY 7.0 7.0 7.0 
ALA 12.9 10 7.0 
CYS 0.88 3.0 6.0 
VAL 13.6 11.5 13 
MET 2.3 2.1 2 
ILE 6.0 5.3 6.0 
LEU 5.5 4.0 3.0 
TYR 2.1 2.1 2.0 
PHE 7.8 7.0 7.0 
F11S 4.2 4.3 4.0 
LYS 15.0 12.0 9 
ARG 17.2 12.6 8 
TRP - - 3 
TOTAL 120 
Table 19. Comparison by amino acid analysis of the crude and gel filtered 
products. 
Sequencing analysis of the partially purified product showed high 
levels of serine over the first three cycles as expected. 
Molecular weight gel electrophoresis run against a series of standards 
showed a broad band around 12,000-14,000. This appeared to indicate 
the presence of a significant number of deletion sequences. 
110 
Appendix I 
The nitrogen bubbler apparatus for manual synthesis: 
During the synthesis the peptide-resin, contained within the cylindrical 
reaction vessel, is agitated with nitrogen. Reagents are added manually 
from the top and removed under suction through the bottom of the 
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